EWMA Journal May 2008

KdajbZ CjbWZg ' BVn '%%EjWa^h]ZY Wn :jgdeZVc LdjcY BVcV\ZbZci 6hhdX^Vi^dc

N

EW

G

6

N G

; 9 > H8 D

: < D 6 K: N D K

W

OR

E H LDS D W IT H I N W O U N

I L A

N

EWMA Council

I]Z :LB6 ?djgcVa ISSN number: 1609-2759 Volume 8, No 2, May, 2008 :aZXigdc^X HjeeaZbZci BVn '%%-/ www.ewma.org I]Z ?djgcVa d[ i]Z :jgdeZVc LdjcY BVcV\ZbZci 6hhdX^Vi^dc Published three times a year

Marco Romanelli President

:Y^idg^Va 7dVgY Carol Dealey, :Y^idg Deborah Hofman, :Y^idg :aZXigdc^X HjeeaZbZci

Peter Franks Immediate Past President

Sue Bale Michelle Briggs Finn Gottrup E. Andrea Nelson Marco Romanelli Zbigniew Rybak Peter Vowden

Finn Gottrup Recorder

Luc Gryson Treasurer

Zena Moore Secretary

Carol Dealey

Marcus Gürgen

:LB6 lZW h^iZ www.ewma.org ;dg bZbWZgh]^e Veea^XVi^dc!

XdggZhedcYZcXZ! egdheZXi^kZ ejWa^XVi^dch VcY VYkZgi^h^c\ please contact: :LB6 Business Office Congress Consultants Martensens Allé 8 1828 Frederiksberg C, Denmark.

Tel: (+45) 7020 0305 Fax: (+45) 7020 0315 ewma@ewma.org AVndji/ Birgitte Clematide

Sue Bale

Judit Daróczy

Deborah Hofman

EWMA Journal Editor

Christine Moffatt

Christina Lindholm

Position Document Editor

E. Andrea Nelson

Patricia Price

Eg^ciZY Wn/ Kailow Graphic A/S, Denmark Copies printed: 13,000 Eg^XZh/ Distributed free of charge to members of the European Wound Management Association and members of co-operating associations.

Individual subscription per issue: 7.50` Libraries and institutions per issue: 25` I]Z cZmi ^hhjZ will be published October 2008.

Prospective material for publication must be with the editors as soon as possible and no later than 1 August 2008 The contents of articles and letters in :LB6 Journal do not necessarily reflect the opinions of the Editors or the European Wound Management Association.

Copyright of all published material and illustrations is the property of the European Wound Management Association. However, provided prior written consent for their reproduction obtained from both the Author and :LB6 via the Editorial Board of the Journal, and proper acknowledgement and printed, such permission will normally be readily granted.

Requests to reproduce material should state where material is to be published, and, if it is abstracted, summarised, or abbreviated, then the proposed new text should be sent to the :LB6 Journal Editor for final approval.

Zbigniew Rybak

Salla Seppänen

José Verdú Soriano

8D"DE:G6I>C< DG<6C>H6I>DCH¼ 7D6G9

Rita Videira

Peter Vowden

M.A. Lassing-Kroonenberg, the Netherlands Goran Lazovic, Serbia Christina Lindholm, Sweden Sandi Luft, Slovenia Christine Moffatt, UK Sonia Muzikants, Sweden Karl-Christian Münter, Germany Guðbjörg Pálsdóttir, Iceland Salla Seppänen, Finland José Verdú Soriano, Spain Luc Tèot, France Anne Wilson, UK Carolyn Wyndham-White, Switzerland Skender Zatriqi, Kosova

Rokas Bagdonas, Lithuania Pauline Beldon, UK Andrea Bellingeri, Italy Saša Borović, Serbia Rosine van den Bulck, Belgium Mike Clark, UK Mark Collier, UK Rodica Crutescu, Romania Valentina Dini, Italy Bülent Erdogăn, Turkey Milada Francu, Czech Republic Kátia Furtado, Portugal Georgina Gethin, Ireland

Finn Gottrup, Denmark Luc Gryson, Belgium Marcus Gürgen, Norway Mária Hok, Hungary Gabriela Hösl, Austria Hunyadi János, Hungary Arkadiusz Jawień, Poland Els Jonckheere, Belgium Aníbal Justiniano, Portugal Martin Koschnik, Germany Jozefa Koskova, Slovak Republic Nastja Kucišec-Tepeš, Croatia Aleksandra Kuspelo, Latvia

:Y^idg^Va 7dVgY BZbWZgh Carol Dealey, UK (Editor) Sue Bale, UK Michelle Briggs, UK Finn Gottrup, Denmark Deborah Hofman, UK E. Andrea Nelson, UK Marco Romanelli, Italy Zbigniew Rybak, Poland Peter Vowden, UK

:LB6 ?djgcVa HX^Zci^ÄX GZk^Zl EVcZa Paulo Jorge Pereira Alves, Portugal Zena Moore, Ireland Caroline Amery, UK Karl-Christian Münter, Germany Mark Collier, UK Pedro L. Pancorbo-Hidalgo, Spain Bulent Erdogan, Turkey Patricia Price, UK Madeleine Flanagan, UK Rytis Rimdeika, Lithuania Milada Franců, Czech Republic Salla Seppänen, Finland Peter Franks, UK José Verdú Soriano, Spain Luc Gryson, Belgium Rita Gaspar Videira, Portugal Gabriela Hösl, Austria Carolyn Wyndham-White, Switzerland Zoltán Kökény, Hungary Gerald Zöch, Austria

For contact information, see lll#ZlbV#dg\

'

:LB6

Journal 2008 vol 8 no 2

Dear Reader

W

( :Y^idg^Va 8Vgda 9ZVaZn

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc * IgZVibZci d[ X]gdc^X ldjcYh l^i] Vjidad" \djh eaViZaZi"g^X] eaVhbV BVgXjh < g\Zc

&( Edan]ZmVc^YZ E=B7 VcY 7ZiV^cZ ^c ldjcY XVgZ bVcV\ZbZci @jgi @VZ]c! I]dbVh :WZgaZ^c

&. EVi^Zcih¼ ZmeZg^ZcXZ d[ ldjcY"gZaViZY eV^c/ 6c ^ciZgcVi^dcVa eZgheZXi^kZ :a^oVWZi] ? BjY\Z

(& :[ÄXVXn d[ ]dcZn Vh V YZhadj\]^c\ V\Zci/ dkZgk^Zl d[ XjggZci Zk^YZcXZ <Zdg\^cV <Zi]^c

:7LB (+ 6WhigVXih d[ gZXZci 8dX]gVcZ GZk^Zlh HVaan 7Zaa"HnZg

:LB6 )% LdgaY Jc^dc d[ LdjcY =ZVa^c\ HdX^Zi^Zh 8dc\gZhh '%%9dj\aVh BXFjZZc

)' :LB6 ?djgcVa EgZk^djh >hhjZh )' >ciZgcVi^dcVa ?djgcVah )) :LB6 8dgedgViZ Hedchdgh 8dciVXi 9ViV )* =VgY"id"]ZVa LdjcYh · V ]da^hi^X VeegdVX]! i]Z :LB6 Edh^i^dc 9dXjbZci '%%8]g^hi^cZ Bd[[Vii

8dc[ZgZcXZh )+ 8dc[ZgZcXZ 8VaZcYVg

Dg\Vc^hVi^dch ), H:7>C@D! =jc\Vg^Vc 6hhdX^Vi^dc [dg i]Z >begdkZbZci d[ 8VgZ d[ 8]gdc^X LdjcYh VcY >cXdci^cZci^V )- HL=H! HZgW^Vc LdjcY =ZVa^c\ HdX^Zin *% 8ddeZgVi^c\ Dg\Vc^hVi^dch *& 6hhdX^ViZY Dg\Vc^hVi^dch

elcome to the second issue of the EWMA Journal for 2008. This is also our conference issue, timed to coincide with the 18th Conference of the European Management Society in Lisbon and given to all conference delegates. It also means that the electronic supplement for this issue comprises the abstracts for all the papers and posters being presented at the conference. I believe that this provides readers with a great opportunity to see the wide range of developments in wound management research that will be presented at the conference.

Of course our readership does not just comprise conference delegates as we have a circulation of 13,000 as the Journal is sent to all our members and also to all our 40 cooperating organisations. It is important not to forget those who access the journal via the internet as this is increasing in number. In November 2007 there were 960 hits for Issue 3 rising to 1881 hits in February 2008 for the same issue as well as a further 1205 hits for the first issue of 2008. It would appear that once internet users find the journal website they find it sufficiently useful to revisit it.

The purpose of the Journal is to provide a mix of scientific and clinical papers alongside news of developments in wound care in Europe. I believe that this issue more than fulfils this remit. Three of the papers provide details of studies looking at different methods of wound management, all from different angles and stages in development. For example, Marcus Gürgen reports a small study investigating the use of autologous platelet-rich plasma for chronic wounds which is at the early stages of investigating this product. Thomas Eberlein and Kurt Kähn have investigated methods of wound cleansing, an area worthy of more investigation. I must particularly mention the paper by Georgina Gethin as she was the recipient of a EWMA award to support her PhD studies. It is always encouraging to see the outcome of awards as it helps to reinforce their value, particularly as so few are available for studies in wound healing and management. The fourth research paper is on another important topic: wound-related pain and it is encouraging to see an international study looking at it from the patients’ perspective.

As well as news from some of our co-operating societies, there is information about the World Union of Wound Healing Societies (WUWHS) conference in Toronto in June. As EWMA is one of the co-operating societies for the WUWHS meeting and a member of the WUWHS, it is good to have this opportunity to share further details about the conference, which we hope will be a great success. It would seem that this summer is a great opportunity for learning more about the latest developments in wound healing and management. For those of you not fortunate enough to be able to attend the EWMA conference and/or the WUWHS conference we hope to bring you reports from both conferences in the next issue of the Journal and some of the best conference papers in the next few issues.

So may I wish you an interesting and productive time over the next few months, remembering that we are always interested in receiving papers on all aspects of wounds, their prevention and management. Full details of the instructions for authors can be found on our website: www.ewma.org.

Carol Dealey, EWMA Journal Editor

:LB6

Journal 2008 vol 8 no 2

(

See what Gelling Foam can do for your patients Versiva® XC™ Gelling Foam DressingThe only dressing with the gelling foam advantage, redefining patient care

• Offers more for wound management than just a moist wound environment • Designed to protect periwound skin and reduce the risk of maceration • Comforts patients over time whilst the dressing is in situ and upon removal 1 • Gel cushions in a way that only a Gelling Foam dressing can 2

References: 1. Vanscheidt W, Münter K-C, Klövekorn W, Vin F, Gauthier J-P, Ukat A. A prospective study on the use of a non-adhesive gelling foam dressing on exuding leg ulcers. J Wound Care 2007; 16: 261-265. 2. Bishop S. Versiva® XC™ Gelling Foam Dressing cushioning and protection claims R&D justification.

WHRI2749 MS002 June 2005. Data on file, ConvaTec. ®/TM The following are trade marks of E.R. Squibb & Sons, L.L.C.: Versiva, Versiva XC and Hydrofiber. ConvaTec is an authorised user. ©2008 E.R. Squibb & Sons, L.L.C. 2008. EU-08-780

www.convatec.com

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

IgZVibZci d[ X]gdc^X ldjcYh l^i] Vjidad\djh eaViZaZi"g^X] eaVhbV Abstract Background: One of the emerging new treatments for chronic wounds is the use of autologous platelet-rich plasma. However, there is little experience with this kind of treatment as well as limited proof of its effectiveness.

Aim: The aim of this study was to gain further information about the benefits of platelet-richplasma in chronic wounds.

Materials and methods: Thirteen patients with 14 chronic wounds were enrolled in an open label prospective study. The wounds included had not shown signs of epithelialization over a period of four weeks despite treatment of underlying causes and standard local wound care.

Results: After treatment with platelet-rich plasma, 50% of the wounds had healed, 35.7% had reduced in size and 14.2% were unchanged in terms of area and condition. Recurrencies were not observed during the follow-up period of an average of 34.5 weeks (range 6,5 weeks-52 weeks).

Conclusion: The use of autologous platelet-rich plasma should be reserved for treatment of recalcitrant wounds where there is lack of improvement despite treatment of underlying causes and good local wound care. Further research in form of controlled trials is required.

>CIGD9J8I>DC Wound healing is a complex process mediated by interacting molecular signals involving mediators and cellular events. Platelets play two important roles in wound healing: hemostasis and initiation of wound healing. After platelet activation and clot formation, growth factors are released from G-granules located in the thrombocyte cell membrane. Growth factors work as biologic mediators to promote cellular activity by binding to specific cell surface receptors1,2.

Autologous growth factors from concentrated platelet suspensions have been used to treat chronic wounds for more than twenty years3,

however, there is still a lack of research to prove their effectiveness. However, a few studies with small sample sizes showed promising results with complete wound healing rates between 37.5% and 66%4,5,6.

Eppley, et al. determined platelet numbers and growth factor concentration in platelet-rich plasma produced by one commercially avalaible system (GPS® II, Biomet Biologics, Warsaw, Indiana). They found an 8-fold increase in platelets compared to whole blood. The concentration of growth factors varied from patient to patient, but increased with increasing platelet numbers (Table 1)7.

The aim of this study was to gain further information about the benefits of platelet-rich-plasma in chronic wounds.

BVgXjh < g\Zc! MD, Senior Consultant Surgeon Dept.of Surgery Sørlandet sykehus HF 4400 Flekkefjord Norway marcus.gurgen@sshf.no

IVWaZ &# >cXgZVhZ d[ \gdli] [VXidg XdcXZcigVi^dc ^c eaViZaZi g^X] eaVhbV, <gdli] [VXidg PDGF-H TGF-H1 VEGF EGF IGF

8dcXZcigVi^dc ^c l]daZ WaddY 8dcXZcigVi^dc ^ EGE 3.3 +/-0.9 ng/ml 17 +/- 8 ng/ml 35 +/- 8 ng/ml 120 +/- 42 ng/ml 155 +/- 110 pg/ml 955 +/- 1030 pg/ml 129 +/- 61 pg/ml 470 +/- 320 pg/ml No increase

B6I:G>6AH 6C9 B:I=D9H Materials The wound healing unit at Sørlandet sykehus Flekkefjord in Norway treats about 250 patients with chronic wounds of various origins each year. The use of autologous platelet-rich plasma was introduced to our unit in February 2007. Since there was limited experience with this kind of technology, we decided to do a prospective open-label study on all patients treated during 2007.

From February 2007 until December 2007, 13 patients with 14 recalcitrant leg and foot ulcers of various aetiologies were included in the study.

0

:LB6

Journal 2008 vol 8 no 2

*

;^\jgZ &/ I]Z <EH">>"ijWZ V[iZg he^cc^c\#

;^\jgZ '/ EaViZaZi XdcXZcigViZ VcY i]gdbW^c [dgb V Xadi l]Zc b^mZY ^c V hiZg^aZ XdciV^cZg#

The sample consisted of 3 females and 10 males with an average age of 52.1 years (range 35-76). The largest groups of wound diagnoses were venous leg ulcers (n=6) and diabetic foot ulcers (n=3). The average duration of the ulcers was 6.8 years (range 2 months -21 years).

Since treatment with platelets is regarded as an established method, acceptance from the local ethical committee was not needed. All patients had given their written informed consent before entry to the study.

Methods This was a prospective open label study to look at the effects of treatment with autologous platelet-rich plasma.

Inclusion criteria were chronic wounds with a duration more than 8 weeks that had not shown any progress (decrease in size, formation of granulation tissue, epithelialization) over a four-week period despite treatment of the underlying causes and appropriate local wound treatment.

Wounds had to be free for necrosis. The ankle-brachial pressure index (ABPI) had to be more than 0.6.

Ulcers that showed evident clinical signs of infection or were exudating heavily, were excluded.

Determination of ankle-brachial pressure index was done on all patients.

Venous leg ulcers were assessed by clinical features and by measuring the ankle-brachial pressure index .

All diabetic ulcers were assessed with both ankle-brachial pressure and toe pressure. An ABPI < 0,8 and toe pressures less than 30-50 mmHg indicated arterial disease.

Neuropathy was examined by testing sensibility in diabetic feet with a 10-g-Semmes-Weinstein-monofilament and a 128 MHz-tuning fork.

Wounds were also assessed in terms of formation of granulation tissue, moisture balance, and infection. These assessments were used to describe the wounds as improved, unchanged or deteriorated.

+

;^\jgZ (/ I]Z Xadi XVc WZ Xji VXXdgY^c\ id ldjcY h^oZ WZ[dgZ WZ^c\ igVch[ZggZY id i]Z ldjcY#

Preparation of platelet-rich plasma Platelet-rich plasma gel to treat wounds was prepared by using a desktop centrifugation system (Gravitational platelet separation system, GPS® II, Biomet Biologics Inc., Warsaw, Indiana) and a reaction chamber to produce autologous thrombin (Thrombin Processing Device, TPD™, Thermogenesis Corp., Rancho Cordova, California). Making platelet-rich plasma starts by drawing a volume of 55 ml blood from the patient and mixing it with 5 ml citrate. The blood is then transferred to the GPS®disposable which is placed in a centrifuge. It is spun at 3200 rpm for 15 minutes. During centrifugation, blood is separated into three different fractions: platelet-poor plasma, platelets and white blood cells, and red blood cells (Figure 1). The platelet-poor plasma and the concentrated platelets and white blood cells are drawn from the tube using separate ports. Thrombin is produced by mixing platelet-poor plasma with an ethanol/CaCl2-reagent in the TPD™ reaction chamber. Platelet concentrate and thrombin are then drawn into seperate syringes, the platelet-thrombin ratio at 10:1. The syringes are connected using a Y-connector. When mixed, thrombin activates the platelets. The result is a platelet gel that sticks to the surface of the wound when applied. Growth factors are also released upon platelet activation. Three different methods can be used to apply platelet gel onto wounds. Using the Y-connector, thrombin and platelet concentrate can be sprayed as a steady stream into the wounds. This method fits best to fill cavity wounds. It is also possible to attach a special tip to the Y-connector, which applies the mixture as a fine spray onto more shallow or large wounds. A third possibility is to create a clot in a sterile container, and then transfer the clot as a whole or cut into pieces into the wound (Figure 2, 3). As more experience with this type of treatment was aquired, the latter was preferred due to less leakage, more stable clotting and better utilization of the amount of platelet gel. :LB6

Journal 2008 vol 8 no 2

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

;^\jgZ )/ EVi^Zci cg# ' IVWaZ ' # 6 cZjgd^hX]Zb^X Y^VWZi^X ]ZZa jaXZg eg^dg id igZVibZci l^i] eaViZaZi \Za#

;^\jgZ +/ 9Vn &**/ I]Z ldjcY ]Vh ]ZVaZY V[iZg ild Veea^XVi^dch d[ eaViZaZi \Za! d[["adVY^c\ VcY \ddY adXVa ldjcY XVgZ#

A degradable dressing (Topkin, Biomet Europe, Dordrecht, the Netherlands) and a secondary absorbent layer (Mepilex, Mølnlycke Health Care, Gothenborg, Sweden) were used to cover the wounds. Treatment of the underlying wound causes such as compression therapy for venous ulcers and off-loading for diabetic ulcers was continued.

Outcome measures In order to assess wound healing accurately, we used digital planimetry (Visitrak, Smith & Nephew, Hull, UK) to measure wound sizes. Digital measurements of the ulcers size were routinely taken on day 7 and day 28. As wounds were followed-up, wound tracings were performed about every four weeks.

The primary endpoint was time to healing, and the secondary endpoint was reduction in ulcer size if wounds had not healed.

;^\jgZ */ 9Vn ',/ i]Z ldjcY h^oZ ^h gZYjXZY Wn )% #

G:HJAIH Wounds were measured at day 0 with digital planimetry and showed an average wound size of 6.7 cm2 (range 0.4 cm2 - 22.3 cm2).

On day 7 after treatment, ulcer size had reduced by an average of 31.4% (range 2.1%-77.7%) in 11 of 14 wounds. Two wounds were unchanged in size, and 1 wound had increased in size by 4.3%. 13 wounds were clinically assessed as improved, and 1 as unchanged.

After 28 days, 1 wound had healed completely. Of the remaining ulcers, 12 had decreased in size to an average of 55.2% (range 6.2%-80%) of their original size. All of those were clinically assessed as improved. One wound remained unchanged in both size and condition.

The number of treatments with platelet-derived growth-factors varied from 1-4 (average 2.1 treatments).

Follow-up continued for an average of 8.4 months (range 1.5-12). Two ulcers showed signs of infection during the course of treatment. In both cases, Pseudomonas species were cultured and infections successfully treated with systemic antibiotics. Other side-effects were not recorded.

Seven (50%) of the ulcers healed within an average of 153 days (range 30-317). Of the non-healed wounds, 2 (13.3%) showed signs of improvement within the ďŹ rst 4 weeks, but have since deteriorated. The remaining 5 (35.7%) of the wounds continued to show improvement and are between 68.7% and 6.8% of their original size.

(Table 2) Recurrencies were not observed.

9>H8JHH>DC Wound healing is a complex process that is regulated by interactions between a large number of cell types, extracellular matrix proteins and mediators such as cytokines and growth factors. Lack of balance between these interactions may result in a chronic wound. One possible cause of imbalance in the wound healing process is high bacterial 0

:LB6

Journal 2008 vol 8 no 2

,

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

IVWaZ '# EVi^Zci X]VgVXiZg^hi^Xh Cg#

HZm! V\Z

LdjcY Y^V\cdh^h

9jgVi^dc d[ i]Z ldjcY 10 years

LdjcY h^oZ Xb

1

F, 76

Venous leg ulcer

2 3 4

M, 53 F, 64 M, 56

Neuroischemic diabetic heel ulcer Neuroischemic diabetic heel ulcer Traumatic leg ulcer associated with an open distal leg fracture Pressure ulcer, leg, associated with spinal cord injury Venous leg ulcer Venous leg ulcer Venous leg ulcer Mixed-etiology leg ulcer

27 weeks 30 weeks 8 weeks

22.3 0.9 4.8

5

M, 39

1 year

5.6

4

7.7

16.1

Reduced by 42.9%

6 7 8 9

M, 50 F, 72 M, 44 M, 55

18 years 21 years 30 weeks 4 years

2.1 1.3 4.4 16.3

4 2 3 1

0.0 31.8 + 4.3 14.2

0.0 69.3 13.1 38.7

M, 39 M, 35

Venous leg ulcer Heel ulcer after cutaneous flap transfer

3 years 21 years

5.7 0.7

4 2

0.0 57.1

6.2 71.4

M, 58 M, 37

Neuropathic diabetic heel ulcer Venous leg ulcers

36 weeks 9 years

0.4 8.0 / 1.5

1 1

50 12.5 / 46.6

50 68.8 / 80

Healed day 233 Healed day 238 Reduced by 93.2% Deteriorated after 10 weeks Reduced by 59.7% Reduced by more than 80% (impossible to measure due to small size) Healed by day 317 Reduced by 72% / healed by day 35

10 11

12 13

21.8

counts leading to a prolonged inflammatory response with high levels of cytokines. This leads to increased production of matrix metalloproteases. High matrix metalloprotease activity results in uncontrolled breakdown of extracellular matrix and growth factors8. If measures are not taken to re-establish the balance between the factors involved, a chronic wound fails to heal.

About 88% of all wounds treated at our wound healing unit heal when the underlying causes are treated and good local wound care is established9. For the remaining wounds, advanced wound-healing strategies can be considered in order to obtain wound closure. A common feature of these advanced strategies is an attempt to influence the bioactive wound environment by, for example, lowering pH-values, applying extracellular matrix, binding matrix metalloproteases, or, in the case of platelet-rich plasma, by increasing numbers of growth factors.

Despite the fact that concentrated platelets have been used to treat chronic wounds for more than 20 years, there is a lack of high-quality studies describing their use in the literature. Literature findings do not allow to draw a clear conclusion on the use of platelet concentrates. Senet, et al. used frozen autologous platelets that had no significant adjuvant effect on healing of chronic venous leg ulcers10.

Reutter, et al. found neoangiogenetic abilities to platelet derived wound healing factors, but not any significant clinical advantage11. Human recombinant epidermal growth factor failed to significantly enhance re-epithelialization in venous leg ulcers12. However, other publications showed encouraging clinical results with the use of growth factors -

CjbWZg d[ "X]Vc\Z "X]Vc\Z GZhjai 9ZXZbWZg i gZVibZcih ^c VgZV Vi ^c VgZV Vi '%%, YVn , YVn'1 22.5 27.1 Deteriorated, no signs of epithelialization 2 23.3 49.7 Healed day 155 1 77.7 100 Healed day 30 1 2.1 16.6 Healed day 62

in in both venous and diabetic ulcers13,14,15,16. Crovetti, et al., McAleer, et al., and Steenvorde, et al. reported wound closure rates in recalcitrant ulcers between 37.5% and 66%4,5,6. The results of this small sample of patients show that 50% of all wounds healed.

Treatment with platelet-rich plasma was reserved for patients with wounds that had not healed despite the use of other treatment strategies. Some of these prior treatments lasted for many years as the average duration of ulcers treated in this study (6.8 years) shows. In those cases, the use of platelet-rich plasma not only lead to wound closures, but also to improved the healing time. The average healing time for the wounds that closed was less than 6 months.

42,8% of 7 venous ulcers in this study healed within 6 months after treatment with platelet-rich plasma and twolayer compression bandage. Nelson, et al. showed 67% healing rates of venous ulcers within 24 weeks when using four-layer compression therapy and 49% healing rates when using single-layer compression therapy17. However, it might be difficult to compare outcomes because of the low number of patients included in the present study.

Two minor complications in form of infection with Pseudomonas aeruginosa were observed. Both wounds were cultured for Pseudomonas aeruginosa prior to platelet gel treatment. In both cases, platelet-rich plasma was sprayed on the wounds. The clot that forms in the wound after spraying does not seem to be as stable as the clot produced in a sterile container. There is also some leakage when spraying, which may contribute to an excessively 0 :LB6

Journal 2008 vol 8 no 2

0".& +!

0%" /(&+

%" +"3 "-&)"4 $ &/ ." ,**"+!"! #,. 3,1+!/ 3&0% &+ ." /&+$ /&$+/ ,# 0".& ) &+#)1"+ " +! 3%"." %" )&+$ !,"/ +,0 -.,$."// +,.* ))5 "-&)"4 $ &/ /1-".&,. ,* &+ 0&,+ ,# /&)2". +! #"0 /,#0 /&)& ,+" 0" %+,),$5 "-&)"4 $ &+ 0&2 0"/ 0".& &+ *&+10"/ +! ) /0/ #,.

1- 0, ! 5/ %" #"0 0" %+,),$5 *&+&*&/"/ 0. 1* 0, 0%" 3,1+! /1..,1+!&+$ /(&+ +! - &+ 0, 0%" - 0&"+0 %".&+"' ! "0 ) 1/0 &+"! +! &+/0 +0 +0&*& ., & ) "##" 0 ,# /&)2". &*-."$+ 0"! #, * !."//&+$ ,+ ,**,+ 3,1+! - 0%,$"+/ ,/0". -."/"+0 0&,+ 0% ,+$."// ) /$,3

8)+)5 (" " )0% ." -1 ) ,4

80" ,.$ 3"!"+ %,+"

333 *,)+)5 (" ,* %" /5* ,) +! 0%" 3,.! * .( ." ,0% ."$&/0"."! 0. !"* .(/ ,. 0. !"* .( -"+!&+$/ ,# 8)+)5 (" " )0% ."

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

moist wound environment, creating suitable conditions for Pseudomonas aeruginosa growth. This is another reason why the external clot is preferred over the spraying technique.

One final reason that the externally-created clot is preferred is that less platelet concentrate is lost during application. When spraying platelet concentrate onto a smaller and/or more shallow wound, some often has to be discarded because it seeps beyond the edges of the wound.

An externally-created clot can easily be cut or formed in accordance to ulcer size and fashion. Thus a larger amount of growth factors are retained in the wound bed to benefit the healing process.

No pattern in the speed of wound healing could not be discerned. Some wounds showed rapid progression of healing after application of concentrated platelet gel, but later slowed down, and in some cases the wounds began deteriorating again. Other wounds did not seem to demonstrate any early healing after treatment, but showed significant progress by the end. There is no plausible explanation for this. To date, there has been no determination of a standard treatment frequency or duration. The treatment program of Crovetti, et al. recommends weekly application of platelet gel. Complete healing was achieved in 9 wounds with an average of 10 applications4. In this study, wound closure occured in 7 wounds with an average of 1.7 platelet gel applications. Crovetti, et al. used a different system to prepare platelet gel, which may have resulted in different concentrations of platelets and growth factors that were applied to the wounds.

A possible treatment protocol based on the experiences gained during this study is to repeat the application of platelet gel at least 3 times over a 6- to 9-week period, and to measure wound sizes regularly. If the wound does not show progress 4-6 weeks after cessation of treatment, a new course of three applications is recommended.

A single treatment cost about 900 Euro, which makes it a costly method. The time needed for preparation and application of platelet-rich plasma is about 90 minutes.

However, the use of autologous platelets seems to be costeffective since ulcers that did not show improvement prior to treatment healed.

Implications for Clinical Practice The preparation and application of platelet-rich plasma can be considered in case of non-healing wounds who do not respond to treatment of the underlying causes and good local wound care. The procedure of preparing platelet gel is easy to learn and reliable. Platelet gel prepared as an external clot seems to be easier to handle. It probably also allows better utilization af the amount of growth factors prepared.

Further Research Controlled studies with sufficient sample sizes have to be initiated. Cost-effectiveness should assessed when doing those studies. As there are several manufacturers providing equipment for in-hospital production of platelet-rich plasma, the different systems must be examined for differences in increase in platelets, growth factor concentrations, preparation time, and applicability.

8DC8AJH>DC The use of platelet-rich plasma can be an option when treating recalcitrant wounds of differing aetiologies.

It should be reserved to wounds that do not show any progress after 6 months with treatment of wound aetiology and standard wound care.

Further research in the field is required. Controlled studies with sufficient sample sizes are needed to prove the efficacy of platelet-rich plasma to treat wounds. Such studies should focus on outcomes as well as for variations in platelet counts, growth factor concentrations, and applicability and cost-effectiveness. The results of this study encourage the author to try to start a Norwegian multi8 center trial.

GZ[ZgZcXZh/ 1. Ernesto C. Clinical review 35: Growth factors and their potential clinical value. J Clin Endocrinol Metabol 1992; 75: 1-4.

2. Rothe M, Falanga V. Growth factors. Arch Dermatol 1989; 125: 1390-1398.

3. Knighton DR, Ciresi K, Fiegel VD, et al. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986; 204: 322-0.

4. Crovetti G, Martinelli G, Issi M, et al. Platelet gel for healing cutaneous chronic wounds. Transus Apher Sci 2004; 30: 145-1.

6gZ ndj ^ciZgZhiZY ^c hjWb^ii^c\ Vc Vgi^XaZ dg eVeZg [dg :LB6 ?djgcVa4 GZVY djg Vji]dg \j^YZa^cZh Vi lll#ZlbV#dg\$Zc\a^h]$Vji]dg\j^YZ

&%

5. McAleer JP, Kaplan E, Persich G. Efficacy of concentrated autologous platelet-derived growth factors in chronic lower-extremity wounds. J Am Podiatr Med Assoc 2006; 96 :482-8.

6. Steenvorde P, van Doorn LP, Naves C., et al. Use of autologous platelet-rich fibrin on hard-to-heal wounds. J Wound Care 2008; 17: 60-3.

7. Eppley BL, Woodall JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114: 1502-8.

8. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen 1996; 4: 411-420.

9. Gürgen M. The TIME wound management system used on 100 patients at a wound clinic. In: Dealey C, editor; Proceedings of the 17th Conference of the European Wound Management Association; 2007, May 2-4; Glasgow, UK. European Wound Healing Association; 2007. p.133.

:LB6

Journal 2008 vol 8 no 2

S 02 04 - * Trademark of Johnson & Johnson - X-STATIC is a registered Trademark of Noble Fiber Technologies Inc

Progressive Strength

SILVERCEL* dressing uses new hydro-alginate technology to complement the effectiveness of silver release. It is a dressing that becomes stronger as it absorbs, facilitating removal from the wound. Clinically tested, SILVERCEL* dressing encourages healing even in very wet wound situations by providing an optimal moist wound environment. The sustained and balanced release of silver ions kills a broad spectrum of microorganisms associated with the bacterial colonization and infection of wounds, including MRSA, MRSE and VRE.

The proven solution for exuding wounds.

Delivered by the Biatain range

Biatain.

For exuding wounds

Contreet / Biatain – Ag For exuding wounds at risk of infection

Biatain – Ibu For exuding wounds with wound pain due to tissue damage

The complete dressing range for exuding wounds The primary challenge in the treatment of exuding wounds is to maintain a moist condition and control the exudation at the same time. That is why we developed the unique Biatain foam to provide superior absorption and retention properties. But we did not stop at that.

We also developed a unique technology for continuous release of silver and ibuprofen into the wound. So if your objective is faster wound healing the Biatain range can deliver the superior solution – whether if it is a matter of exudation management alone or in a combination with bacteria overload and wound pain. For more information about Biatain, Contreet / Biatain – Ag or Biatain – Ibu please visit www.woundcare.coloplast.com

and Biatain are are registered trademarks of Coloplast A/S or related companies. © 2007-11. All rights reserved Coloplast A/S, 3050 Denmark.

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

Edan]ZmVc^YZ E=B7 VcY 7ZiV^cZ ^c ldjcY XVgZ bVcV\ZbZci >CIGD9J8I>DC The main problems related to non-healing wounds are poor cleansing and insufficient attention to bio-burden especially in outpatient wound care where about 90% of chronic wounds are treated.

Wound coatings activate the innate immune system, favour the growth of bacteria, and are the origin of reactive oxygen species (ROS) 1 and pro-inflammatory mediators. These agents destroy viable tissue and trigger massive granulocyte accumulation in the microvasculature resulting in obstruction of microcirculation at the wound edges2. Thus, the aim of wound cleansing should be complete removal of all non-vital materials.

Thorough and gentle wound cleansing is crucial for proper wound bed preparation allowing the wound to heal faster.

Wound cleansing by rinsing is routinely used in wound bed preparation. Considering the hydrophobic and polymeric nature of the principal components of wound coatings it is assumed that the type of rinsing solution may be of particular importance to the effectiveness of cleansing.

Wound coatings contain denaturated proteins, lipids from cell debris, and cross-linked fibrin all in need of a surface tension reducing agent for removal and solubilisation.

In home care the first choice “solution” for wound cleansing is often non-sterile tap water usually contaminated with Pseudomonas aeruginosa, followed by re- or overused flasks of saline or Ringer’s solution often contaminated by species of the normal human flora or the natural environment3. Non-sterile wound rinsing may be “costeffective” at first glance however it is definitely not state-of-the-art of wound management.

To compare the cleansing efficiencies of wound rinsing solutions under controlled testing conditions an in vitro model that mimics wound coatings was developed. Removal of test coatings were analysed using saline, Ringer’s solution and a special wound rinsing solution containing Poly (hexamethylenbiguanide)hydrochloride (PHMB) and a Betaine surfactant. Subsequently the in vitro

results were verified by a retrospective analysis of healing processes of chronic wounds of the type “Ulcus cruris venosum”.

B6I:G>6A 6C9 B:I=D9H Preparation of test wound coatings Outdated frozen fresh plasma (FFP), anti-coagulated and stabilised with CPS (citrate, phosphate, dextrose) was thawed, applied to diagnostic slides (adhesive design) and dried on them overnight.

For fibrin formation one volume part of 1.8 M CaCl2 solution was added to nine volume parts of CPD plasma. The fibrin formation started immediately after mixing of the volume parts on the slide.

Wound rinsing solutions Physiological saline solution (0.9% NaCl), Ringer’s infusion solution (0.860% NaCl, 0.030% KCl, and 0.033% CaCl2·2H2O) and a solution containing 0.1% Polyhexamethylene Biguanide and 0.1% Undecylenamidopropyl Betaine (Prontosan®) were obtained from B. Braun Melsungen AG.

@jgi @VZ]c, Dr. rer. nat.

MSc (biology and chemistry), PhD K2 Hygiene Dienstleistungen Haidstrasse 48 D-67431 Aschaffenburg, Germany k2-hygiene@t-online.de I]dbVh :WZgaZ^c, Dr.med.

Dermatologe/Venerologe - Allergologe Fachexperte für die Zertifizierung von QM-Systemen nach EN ISO 9001:2000 Ossiacher Straße 9 D-90475 Nürnberg, Germany

Protein measurement Proteins were removed from the test coatings either by dissolving or by inclusion in micellar colloids of detergent. Dissolved proteins were detected by means of a modified Biuret reaction reagent (Roti®-Quant universal, Carl Roth GmbH & Co. KG). Soluble proteins formed complexes of a violet colour with copper ions of the reagent (see figure 1). The extinction at 503 nm was directly proportional to the protein concentration.

Denaturated proteins enclosed in micelles were not detected by the Biuret reaction.

In vitro test design Test slides with dried-on blood plasma or fibrin were placed in histological staining troughs filled with test solutions. Each test preparation was accompanied in parallel by a blind preparation (rinsing solution without test slides). After 2.5, 0

:LB6

Journal 2008 vol 8 no 2

&(

;^\# &/ ;dgbVi^dc d[ i]Z k^daZi XdbeaZm WZilZZc c^igd\Zc Vidbh d[ eZei^YZ WdcYh VcY XdeeZg ^dch d[ i]Z 7^jgZi gZV\Zci#

;^\# 'V/ EgdiZ^c XdcXZcigVi^dch ^c i]Z hjeZgcViVcih d[ i]Z iZhi hZg^Zh l^i] ;;E ha^YZh#

30, and 60 minutes 1.5 ml aliquots were transferred to reaction vessels and centrifuged immediately at 2,500 g for 2 minutes. 0.1 ml supernatant was mixed with 0.1 ml distilled water and 0.8 ml protein reagent. The extinction was measured within 30 minutes at 503 nm (Beckman DU-600 photometer). After subtraction of blind values the extinction values of probes were plotted against incubation time. For calibration plots 0.1 ml test solution, 0.1 ml of a bovine serum albumin (BSA) solution, and 0.8 ml protein reagent were mixed.

Clinical data For retrospective analysis of wound healing processes, medical records of 112 patients with Ulcus cruris venosum were evaluated. Wounds of patients were routinely cleansed using PHMB and Betaine containing rinsing solution (n=59) or saline and Ringer’s solution (n=53) respectively. The time to wound healing in both groups was compared statistically.

Inclusion (+) / exclusion (-) criteria were: + wound at least three months old + confirmed diagnosis “Ulcus cruris venosum” + wound treatment according to the recommendations of “moist wound treatment” + compression therapy in cases of venous ulcers by short stretch bandaging + clear documentation of the type of rinsing solution used during wound treatment – persistent, severe arterial circulation disorders (Fontaine stage II) Statistical evaluation The time to wound healing data were analysed using the Kaplan-Meier method and the means of the two patient groups were compared with the log rank test. In both patient groups there were no drop-outs. The total observation period was predisposed to six months and started with admission. About 90% of wounds healed within the observation period in both patient groups.

&)

;^\# (/ 9^h^ciZ\gVi^dc d[ iZhi XdVi^c\h Wn hjg[VXiVci iZhi ha^YZh ^cXjWViZY ^c EZig^"Y^h]Zh

Infection rates were compared and evaluated using Fischer’s chi-square test.

G:HJAIH Effect of rinsing solutions on test coatings During the incubation period of standardised test slides (coated with either FP or fibrin) the protein concentration in all three wound rinsing solutions increased almost linearly, thus meaning that no saturation was reached under the test conditions. Concentrations of dissolved protein were lowest in Ringer’s solution and 3.5 times (FFP) and 5 times (fibrin) higher in saline. Most proteins were solved in Prontosan®. Compared with saline, the concentrations were 25% (FFP) and 75% (fibrin slides) higher (see figures 2a and 2b).

In contrast to saline and Ringer’s solution the PHMB/ Betaine containing wound rinsing solution disintegrated test coatings and solubilised denaturated proteins by enclosing them in micelles (see figure 3). Micellar colloids show strong refraction and hence turbidity in the PHMB/ Betaine containing solution increased during incubation time.

:LB6

Journal 2008 vol 8 no 2

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

;^\# 'W/ EgdiZ^c XdcXZcigVi^dch ^c i]Z hjeZgcViVci d[ i]Z iZhi hZg^Zh l^i] ÃWg^c ha^YZh#

;^\#)/ 8aZVch^c\ d[ Y^VWZi^X [ddi jaXZg

Effect of rinsing solutions on wound healing All wounds were cleansed by thorough and gentle rinsing using either a special wound rinsing solution or saline/ Ringer’s solution. The effect of a simple cleansing procedure is shown in figures 4 a-c.

There were significant differences between the two patient groups concerning wound healing. In the group treated with PHMB/Betaine containing wound rinsing solution the wound healing rate was faster. After three months already 60% (n=35) of wounds were healed compared to 28% (n=15) in the group treated with saline or Ringer’s solution (see table 1). At the end of the observation period of six months the healing rates in both groups were proved satisfactory (97% and 89%). Mean time to healing in the PHMB/Betaine group was superior to the saline/ Ringer’s solution group (see figure 4). In the latter there was a healing delay of more than one month: 4.42 ± 1.41 compared to 3.31 ± 1.32 months (p < 0.001).

V V[iZg gZbdk^c\ XdckZci^dcVa ldjcY YgZhh^c\h IVWaZ &# LdjcY ]ZVa^c\ gViZh ^c eVi^Zcih igZViZY l^i] Y^[[ZgZci ineZh d[ ldjcY g^ch^c\ hdaji^dch @VeaVc"BZ^Zg"bZi]dY number of patients rinsing solution time scale end of 1st month end of 2nd month end of 3rd month end of 4th month end of 5th month end of 6th month

53 59 saline or Ringer’s PHMB / Betaine wound healing rate (%) 2 7 9 29 28 59 51 81 68 93 89 97

W '% b^cjiZh aViZg V[iZg XaZVch^c\ jh^c\ E=B7 VcY 7ZiV^cZ XdciV^c^c\ ldjcY g^ch^c\ hdaji^dc

During the period of wound treatment infection rates were 3% (n=2) in the PHMB/Betaine group compared to 13% (n=7) in the saline/Ringer’s solution group (p = 0.056).

X i]gZZ YVnh aViZg V[iZg gZbdk^c\ d[ ldjcY YgZhh^c\h

9>H8JHH>DC When proteins are dissolved in water each protein molecule is included in a structured hydration sheath of water molecules which prevents aggregate formation and precipitation. Saline and Ringer’s solution, both regularly used in wound care practices, contain monovalent and bivalent salt ions (Na+, Ca++ or Cl-) which bind many water molecules (about 185 for monovalent ions) and therefore compete with proteins for the water molecules. Increasing 0

:LB6

Journal 2008 vol 8 no 2

&*

;^\# */ I^bZ XdjghZ d[ ldjcY ]ZVa^c\ ^c eVi^Zcih igZViZY l^i] Y^[[ZgZci ineZh d[ g^ch^c\ hdaji^dch/ E=B7 VcY 7ZiV^cZ XdciV^c^c\ ldjcY g^ch^c\ hdaji^dc WajZ VcY hVa^cZ dg G^c\Zg»h hdaji^dc dgVc\Z #

salt concentrations (exact ionic strength*) destabilize the hydration sheaths of proteins resulting in aggregate formation and precipitation (salting-out effect). In particular salts with polyvalent ions like Ca++ in Ringer’s solution reduce the solubility of proteins4.

In an in vitro model for wound coatings (FFP/fibrin on adhesive glass slides) differences between wound rinsing solutions with regard to protein solubilisation could be demonstrated. Ringer‘s solution, which contains 2.2 mM divalent calcium ions was less effective than saline solution in dissolving denaturated proteins. Compared with saline, only 20-30% of the amount of protein dissolved in Ringer‘s solution. A PHMB and Betaine containing special wound rinsing solution which does not contain any salt additive was most suitable for dissolving proteins from test coatings. The Betaine surfactant improved protein removal by disintegration of coatings and formation of micellar colloids.

Results obtained by using the in vitro wound coating model were verified by retrospective analysis of chronic wounds (venous leg ulcers). Improved cleansing efficiency should also improve wound healing by reducing oxidative stress and levels of pro-inflammatory mediators in the wounds.

Actually this hypothesis was supported by retrospective clinical data. Wounds treated with PHMB/Betaine containing wound rinsing solution revealed superior wound healing. Mean time to healing was about three instead of four months. Obviously the local wound milieu favoured the occurrence of reparative processes when rinsed with PHMB/Betaine solution. These findings are consistent with recent reports on effects of PHMB/Betaine solution5,6,7.

Another effect for better wound healing was the reduced infection rate in the PHMB/Betaine treated patient group (3% versus 13%, p = 0.056). Due to low overall infection rates in the wound care unit the difference did not reach the significance level of 5% (p < 0.05). Infections were treated by infusion of antibiotics. In both groups local antiseptics were not applied during the period of observation.

Low infection rates during wound management reduce complications in wound care, improve wound healing rates and bring down costs. Considering that infection rates below 2% are difficult to realise 3% in the PHMB/Betaine group are near the optimum.

Wound healing is a highly complicated multifactorial process and requires a sophisticated local wound management.

The most important point is to follow the recommendations of moist wound treatment as defined by Falanga8 and Sibbald9. Typically, neutral physiological solutions are used for that purpose. However, PHMB/Betaine containing wound rinsing solutions may be superior to salt solutions.

Betaine forms micelles and improves solubilisation of hydrophobic material from wounds. Poly(hexamethylenbigu anide)hydrochloride (PHMB) is an antimicrobial agent widely used as a preservative in commercial and industrial settings. The most common use is as an algicide, fungicide, and sanitizer in swimming pool systems. In medicine PHMB was introduced by Willenegger in 199410 as an antiseptic in abdominal surgery. Over the past years end-use (ready-to-use) wound care products containing PHMB have been successfully launched including wound rinsing solutions, wound gels and dressings.

Special features qualify PHMB for growing and effective application in wound care management. To begin with PHMB is very active against bacteria and Candida in

* The ionic strength I of a salt is half the sum of the terms obtained by multiplying concentration ci and charge z1 of the dissolved ions.

&+

:LB6

Journal 2008 vol 8 no 2

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

low concentrations (0.01 to 0.1% (w/v)). In addition, the acute toxicity of PHMB is low for both oral and dermal use. The no observable effect levels (NOEL) in dogs are 90 mg/kg bw/day for systemic toxicity and 45 mg/kg bw/ day for chronic toxicity (oral route both). For individual cases slight or moderate dermal irritations and/or allergic type reactions were reported. However, compared with other antimicrobial agents the safety margin of PMHB is extremely high11.

8DC8AJH>DCH In wound treatment â&#x20AC;&#x153;cleanlinessâ&#x20AC;&#x153; (no coatings, reduction of detritus, removal of necrotic tissues, low microbial bioburden) is generally considered an important factor for improving secondary wound healing without major problems. This fact applies to both acute and chronic wounds.

National and international professional associations and societies recommend accepted standard procedures for optimal wound cleansing and wound bed preparation to obtain favourable conditions for healing. Particular attention is given to the risk of infection and to break the vicious circle of colonisation, infection and non-healing.

In this context and in order to achieve the necrosis- and detritus-free state of the wound great care must be taken

to ensure that there is no damage or harm to vital and especially to naturally functional important structures.

Keeping this objective in mind, the application of PHMB/ Betaine containing wound rinsing solutions seems to be a highly appropriate concept in supporting these effects and 8 to promote wound healing.

References 1. James TJ, Hughes MA, Cherry GW, Taylor RP. Evidence of oxidative stress in chronic venous ulcers. Wound Rep Reg 2003; 11: 172-176 2. Kaehn K. EntzĂźndungsreaktionen des Endothels und chronische Wunden.

Zeitschrift fĂźr Wundheilung 2004; 4: 161-165 3. Gouveia JCF. Is it safe to use saline solution to clean wounds?

EWMA Journal 2007; 2: 7-12 4. Lehninger AL (ed). Biochemistry, 6th printing; Part1, Chapter 7: Proteins â&#x20AC;&#x201C; behaviour in solution. Worth Publishers N.Y. 1972 5. Eberlein T, Fendler H, Andriessen A. ProntosanÂŽ-LĂśsung oder Standard-Behandlung? Die Schwester Der PďŹ&#x201A;eger 2006; 9: 2-4 6. Horrocks A: Prontosan wound irrigation and gel: management of chronic wounds.

Br J Nurs. 2006; 15: 1224-1228 7. Kramer A, Roth B, MĂźller G. Rudolph P, KlĂścker N. InďŹ&#x201A;uence of the antiseptic agents Polyhexanide and Octenidine on FL cells and on healing of experimental superďŹ cial aseptic wounds in piglets. Skin Pharmacol Physiol 2004; 17: 141-146 8. Falanga V. ClassiďŹ cation for Wound Bed Preparation and Stimulation of Chronic Wounds. Wound Repair and Regeneration 2000; 8: 347â&#x20AC;&#x201C;352 9. Sibbald RG, Williamson D, Orstedt HL, Campbell K, Keast D, Krasner D, Sibbald D. Preparing the Wound Bed â&#x20AC;&#x201C; Debridement, Bacterial Balance, and Moisture Balance.

Ostomy Wound Management 2000; 46: 14â&#x20AC;&#x201C;35 10. Willenegger H. Klinische Erfahrungen mit einem neuen Antiinfektivum.

Hygiene Medizin 1994; 4: 227-233 11. Kramer A. Stellenwert der Infektionsprophylaxe und â&#x20AC;&#x201C;therapie mit lokalen Antiinfektiva: 15-25. In: Kramer A, Wendt M, Werner H-P (eds.). MĂśglichkeiten und Perspektiven der klinischen Antiseptik. mhp-Verlag GmbH Wiesbaden 1995

:LB6

Journal 2008 vol 8 no 2

&,! "

#

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

EVi^Zcih» ZmeZg^ZcXZ d[ ldjcY"gZaViZY eV^c/ an international perspective Abstract Background: Chronic wound healing is generally a long and uncomfortable process. Consequently, an understanding of wound-related pain from the patients’ point of view and evaluation of the effect of pain on a persons’ daily life is fundamental to their holistic management.

Aim: The aim of the study was to involve patients in discussion about their wound-related pain experiences in order to inform the development of a questionnaire, based on the views of patients from different cultural backgrounds. This study represented one of the preliminary phases of an international survey which aimed to collect data on patient’s wound-related pain experiences; from 15 countries world-wide.

Method: An international qualitative study was conducted in patients presenting with chronic wounds to identify those aspects of wound-related pain which created most concern. French, British and Canadian patients with chronic wounds participated in a series of focus group studies.

Results / Findings: Although a number of similar patient issues were apparent in all three countries, specific cultural differences were also observed: the French group expressed particular concern with body image, the British group were uncomfortable with medication use and the Canadian group were anxious about financial loss and apprehensive of the healthcare system.

Conclusion: Wound-related pain can have a huge impact on a persons’ everyday life and as such each patient’s needs should be recognised and considered.

>CIGD9J8I>DC Chronic wound pain is associated with negative mood, decreased activities of daily living, sleep disturbance, reduced mobility and social withdrawal1,2,3,4,5. Qualitative research in this area has identified numerous aspects of pain and discomfort which have a negative impact on qual-

ity of life among patients with chronic wounds6.

Activities that are important to the maintenance of daily functioning such as working, walking, standing and climbing stairs can often exacerbate pain in wounds5,7 and thus lead to restricted lifestyle and a sense of confinement3. These feelings are often amplified by sleep disturbance and can eventually result in social withdrawal in some instances8. There is a strong connection between pain and an individual’s sense of well-being. Negative emotions such as anger, sadness, hopelessness and despair are common in cases where a painful wound is seen to control a person’s existence3,9. It is therefore not surprising to find that a substantial proportion (37.5%) of patients with venous leg ulcers described pain as the worst aspect of having an ulcer10. Various studies of patients with venous leg ulcers11,12,13 and diabetic foot ulcers14 indicate that pain is significantly associated with diminished quality of life and forms a person’s foremost concern in their care15.

G:H:6G8= 9:H><C 6C9 B:I=D9H Four focus groups, each involving five or six patients (total number of participants = 23: 10 male, 13 female) with chronic leg ulceration or diabetic foot ulceration were conducted in France, the United Kingdom and Canada. Focus groups were chosen as this method can elicit a wealth of opinions and emotional processes within a group context. Purposive, non-probabilistic sampling was used to identify specific people who had experience of discomfort and/or pain related to their chronic wound. Only adult patients (18+ years of age) with an active ulcer of over 6 weeks were invited to participate. There were no exclusion related to a predetermined level of intensity of pain experienced at the time of the focus groups, but only those who had some previous or current experience of discomfort/pain related to their wound were invited to participate. The inclusion criteria were deliberately broad in order to capture

:a^oVWZi] ? BjY\Z, MSc, BSc, MChS, SRCh, D.Pod.M1 Hnak^Z BZVjbZ! MD2 @Zk^c Ldd! RN, MSc3 G <Vgn H^WWVaY! MD, FRCPC, MEd3 EVig^X^V : Eg^XZ! PhD, BA (Hons), AFBPsS CHPsychol1 1. Wound

Healing Research Unit, School of Medicine, Cardiff University, Wales, United Kingdom 2. Service de Gérontologie, Hôpital Charles Foix, Ivry sur Seine, France 3. Wound Healing Clinic, Women’s College Hospital, University of Toronto, Canada 8dggZhedcYZcXZ id/ Elizabeth Mudge Cardiff University Department of Wound Healing Upper Ground Floor Heath Park Cardiff CF14 4XN mudgee@whru.co.uk

0 :LB6

Journal 2008 vol 8 no 2

&.

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

6eeZcY^m &# ;D8JH <GDJE HX]ZYjaZ$ Egdbeih EV^c Vi YgZhh^c\ X]Vc\Z egdXZYjgZ ^c eVi^Zcih l^i] X]gdc^X ldjcYh E6GI & ¡ & =djg I^bZ *"&% b^cjiZh

E]VhZ >cigdYjXi^dc

(%")% b^cjiZh

DeZc e]VhZ (Open discussion around experiences of living with a wound including pain experiences)

&% b^cjiZh

7gZV` GZ[gZh]bZcih

Egdbeih Introductions Outline aims of project Experience of living with a wound Experience of pain Intensity and description of pain Timing of discomfort / pain Impact of pain / discomfort on everyday living (including employment and impact on other family members)

E6GI ' ¡ & =djg (%")% b^cjiZh

* b^cjiZh

9^gZXiZY XdckZghVi^dc

LgVe"Je VcY 8adhZ

Parts of the dressing change process â&#x20AC;&#x201C; are they different in terms of discomfort / pain experience? â&#x20AC;˘ Anticipation of dressing change â&#x20AC;˘ Dressing removal â&#x20AC;˘ Cleansing â&#x20AC;˘ Application of new dressing â&#x20AC;˘ Location of the dressing change procedure â&#x20AC;&#x201C; (e.g.: home, outpatient clinic or inpatient clinic) â&#x20AC;˘ Involvement of the patient in the process Residual pain following change Other aspects of wound related pain e.g.: â&#x20AC;˘ Infection â&#x20AC;˘ Surrounding skin Other aspects of treatment related to pain e.g.: â&#x20AC;˘ Use of particular dressings â&#x20AC;˘ Antibiotics What makes the experience worse?

What improves the experience?

What strategies help? â&#x20AC;˘ Is the patient able to self help? â&#x20AC;˘ Where does patient go to ďŹ nd information on strategies to manage pain/ discomfort?

Open question to ensure that all the issues important to the patients and relevant to the topic have been covered.

the full range of experiences related to discomfort/pain and using a purposeful sample was deemed appropriate in order to fully explore the participantsâ&#x20AC;&#x2122; pain experiences.

Following ethical approval and identiďŹ cation through appropriate healthcare staff, patients were sent an information sheet about the study followed by a telephone call one week later. Those patients interested in participating and who had provided written consent were asked attend a speciďŹ ed non-clinical location for a two-hour focus group meeting.

Each focus group was run by one or two facilitators with experience in psychological aspects of wound healing, who explained the aim of the group, conďŹ rmed conďŹ dentiality and emphasized that the focus would be on talking to each other rather than to the researchers. The same schedule (see appendix 1) was followed in all three countries in order to ensure consistency between groups.

'%

The ďŹ rst part of the discussion concentrated on general wound-related pain experiences whereas in the second phase the facilitators focused the discussion around the topic of discomfort and/or pain during the dressing change procedure. Pre-determined open questions/prompts were used to facilitate conversation.

The discussions were tape recorded. The content of the tapes were transcribed by one researcher, conďŹ rmed by a second researcher and veriďŹ ed by the participants at each location. The discussion transcriptions were evaluated by means of content analysis16 which enabled systematic identiďŹ cation of a number of emergent themes representing the participantâ&#x20AC;&#x2122;s responses. Separate analyses were conducted for each group and reliability of themes was veriďŹ ed by a second researcher. The overall results were then further evaluated between the three countries.

0

:LB6

Journal 2008 vol 8 no 2

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

G:HJAIH The participants in all three countries agreed that pain was a constant feature of their wounds but that it varied in intensity throughout the day. Constant pain was perceived by one of the French participants to change one’s appearance; “It shows in the face”, whereas in the Canadian and UK groups, adjectives such as “burning”, “throbbing” and “shooting” were used to describe their everyday pain.

A more intense and sudden pain was also vividly described which caught the participants off guard at any time during the day or night. This pain was considered far more distressing than their “ordinary pain” and was described as follows: Participant (France) – “It’s as if I have a bar behind my thigh and someone is pressing it against me and tightening it up” Participant (UK) – “It’s like an iron band with spikes pressing hard” Participant (Canada) – “Tremendous pain, I crawl on all fours” Participant (France) – “I have the sensation that someone is eating my flesh, like a dog biting me. It hurts terribly”

Quality of Life The impact of pain revealed a number of psychological processes that were common regardless of gender or culture. Many participants felt that wound-related pain reduced their confidence in carrying out everyday tasks and in maintaining social and recreational activities. These feelings manifested themselves by a sense of isolation and a loss of identity which reinforced an awareness that their lives had irreversibly changed: Participant (France) – “It’s only goodbye” Participant (UK) – “It feels like we are been taken over to a different route in life than the one we expected” Participant (Canada) – “You think it’s never going to end” It appeared difficult for the participants to distinguish between the impact of the ulcer and the repercussions of the pain. Nevertheless, a number of points were emphasised.

All of the participants had encountered difficulties with walking and many were afraid of falling:

Participant (UK) – “I always look down when I walk; I am so afraid I am going to fall” Participant (Canada) – “Walking becomes worse as neuropathy slowly progresses and you’re unable to weight-bare. I cry like a baby and I am unable to deal with it”

Driving a car had become difficult or impossible for most of the participants thus increasing their sense of isolation: Participant (France) – “I recently started driving again.

But I cannot drive for long, as I can no longer feel my foot on the pedal” Participant (UK) – “Because of the pain I cannot drive anymore” Participant (Canada) – “You are at the mercy of someone else”

This loss of mobility was perceived by the participants as preventing them from independently performing various tasks of daily living which greatly reduced their sense of well-being and their overall quality of life.

Feeling isolated The participants portrayed stigmatisation caused by having a chronic ulcer. In addition to the negative appearance of the wound and the dressings, pain also contributed to feelings of marginalisation: Participant (France) – “If I haven’t got my morphine … at those times, I just don’t want to see anybody” Participant (UK) – “I had to drop from things I really enjoy” Participant (Canada) – “When in severe pain I do not want to say anything or talk to my family”

Social isolation was frequently linked to a sense of shame: Participant (France) – “I no longer go out because I am ashamed of my stick and my slippers, and above all I am afraid of falling over …I don’t go anywhere unless someone comes with me. I stay at home”

Participant (France) – “I haven’t been able to go walking outside for about six months. I can’t get down the stairs any more”

''

0

:LB6

Journal 2008 vol 8 no 2

Doing the right thing.

With all kinds of wounds.

The recommended treatment for moist wound management by L&R.

®

®

moderately exuding wounds

A + Ag

S u p ra s o r b

lightly exuding wounds

heavily exuding wounds

X

+

so

®

rb ®

the perfect combination for infected wounds

X + PH M B

S

Suprasorb –

rb aso r up

PH

MB

p Su

ra

® prasorb X u S

rb ®

ra

ra

so

rb ®

X

Su

p

32088 / 1106 / e

MedPro Novamed AG Badstrasse 43 CH-9230 Flawil www.novamed.ch

heavily exuding wounds

so

Sup

Lohmann & Rauscher GmbH & Co. KG Postfach 23 43 D-56513 Neuwied www.lohmann-rauscher.de Lohmann & Rauscher GmbH Postfach 222 A-1141 Wien www.lohmann-rauscher.at

moderately exuding wounds

A

lightly exuding wounds

HEALING · PROTECTING · PROVIDING CARE

®

Suprasorb – the perfect combination for non-infected wounds

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

Moreover the participants linked their mood state directly to their wound which was described by one participant as a “depressing disease”. Such emotions were possibly amplified by a common tendency for not wanting to “burden” or “bore” friends or relatives with their feelings: Participant (France) – “It’s not difficult to talk about it but I don’t want to share this painful experience with those close to me” Participant (UK) – “You cannot whinge too much to friends otherwise you will not have any friends … you have to keep it to yourself ” Participant (Canada) – “I am not a complainer …

I don’t want to be a burden” Participant (UK) – “A lot of people did not know of my problem for 20 years; I kept it to myself ”

The participants even intimated that they would avoid speaking to their caregivers or healthcare practitioners about their pain, particularly if they had been seeing them for many years as they felt that they had “said it all before”.

Body image Aesthetic considerations toward both the wound and the dressing further impacted on the participants’ quality of life and these were strongly linked with social isolation.

Negative body image was passionately discussed among the French group: Participant (France) – “A leg ulcer is very ugly” Participant (France) – “It (the dressing) certainly isn’t feminine. That’s why I always wear trousers” Participant (France) – “The bandage is lighter in colour than my leg and is not at all attractive.

I avoid going out”

Embarrassment concerning body image was augmented by wound odour: Participant (France) – “A woman sitting beside me in a waiting-room said about another patient; ‘That woman doesn’t wash, for sure.’ It’s awful isn’t it?”

Sleep deprivation Sleep deprivation was a common discussion point within all the groups and had an overwhelming impact upon their ability to cope with pain and their quality of life:

')

Participant (France) – “At night sometimes it is so bad that I wake up” Participant (UK) – “Every night you’d be rubbing your leg, you don’t know what to do, I get up in the night and walk about, anything, then go back to bed” Participant (Canada) – “I am constantly watching the news or clock for distraction at night”

Healthcare system Frustration with the healthcare system was reported to have a negative influence on wound-related pain experience for some of the participants and was the focus of considerable discussion in the Canadian group. Particular issues concerning frequent turn around of nurses, inconsistency of care, misunderstanding of pain and lack of information caused the participants to loose faith in their healthcare system: Participant (Canada) – “Healthcare providers are geared toward acute injuries; they have no understanding of chronic ulcers”

Furthermore, financial concerns due to time taken off work to attend healthcare appointments or misunderstanding of their condition led to much anxiety and distress: Participant (Canada) – “My work cut off my pension (because they did not consider me to be disabled enough)”

Dressing change Anticipation of the dressing change produced a mixture of positive and negative emotions, but having a fresh dressing put on the wound was generally perceived to be a very painful and fearful time for the participants and represented a permanent reminder of the existence of their wound.

Favourable aspects arose from the fact that changing the dressing relieved the compression, allowed them to bathe their feet and legs or take a shower, observe any changes in the wound and to see the nurse who, in some cases, would be the only social contact of the day.

Dressing the wound was linked to pain and many patients took some form of analgesia before their appointment. Pain was particularly intense when the dressing had adhered to the wound and also during cleansing of the ulcer. In some instances fearful anticipation of these pro0 cedures was intensified by past memories:

:LB6

Journal 2008 vol 8 no 2

ALLEVYN™ Gentle Border

ALLEVYN Gentle

ALLEVYN Ag

EZCARE™

V1STA

Maximising performance and protection.

Minimising pain.

At EWMA this year we are focussing on new therapeutic solutions that maximise performance and protection for your patients while minimising pain: ALLEVYN Ag containing silver combines the antimicrobial protection with all the benefits of triple-action ALLEVYN technology.1 ALLEVYN Gentle and ALLEVYN Gentle Border minimise pain on removal2,3 and provide all the benefits of triple-action ALLEVYN technology.

EZCARE and V1STA provide Negative Pressure Wound Therapy that is gentle on the patient, with proven clinical effects, improving patient outcome and experience4.

Smith & Nephew - your complete solution for wound management.

Wound Management Smith & Nephew Medical Ltd 101 Hessle Road Hull HU3 2BN UK

T 44 (0) 1482 225181 F 44 (0) 1482 328326 www.smith-nephew.com/wound www.allevyn.com www.npwt.com

™Trademark of Smith & Nephew 13125

References: 1. Data on file 0707052 2. Data on file 0711086 3. Data on file 0711087 4. Journal of Woundcare (2006), Vol 15, No. 7 July 2006

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

Participant (France) – “When she scrapes, that’s the worst moment …”

Participant (UK) – “Once you disturb it when you do a dressing you’ve got to wait at least half an hour afterwards for it to settle down where you just don’t want to move from the spot” Participant (Canada) – “When the blade comes out, that’s when my pain level goes through the roof ”

Some participants stated that the dressing change procedure was made worse if the ulcer was left exposed/uncovered for long periods of time and this was linked to a fear and a misunderstanding of infection. Such concerns were amplified by a sense that there were inadequate numbers of staff or resources and that the dressing change procedure was out of their control. However, many participants reported that they felt the dressing change procedure could be improved by continuity of care, regular or familiar healthcare professionals and having a good support network.

Medication Concern about long term use or reliance on pain-relieving medication and fear of poly pharmacy was highlighted by the UK participants and created prominent discussion in this group. Those participants who took ‘pain-killers’ reported that the possibility of delay of the dressing change would cause anxiety which was based on fear that their analgesia could wear off. Many of the participants admitted to using alcohol to calm their nerves yet were concerned about stigma associated with addiction to pain-relieving medication or getting so used to taking tablets that they would lose their effect: Participant (UK) – “I don’t like taking a lot of tablets, not through choice, some tablets make me sick …

I mean you take all these tablets over the years and it says do not take alcohol and you think oh what the hell, a glass of red wine will do wonders” Participant (UK) – I’ve just stopped now (taking analgesics) and try to tolerate the pain you know because you just don’t know what these (tablets) are doing to your insides over the years”

Infection Overwhelmingly the greatest perceived concern in all three countries was that of infection and this was amplified by the knowledge that infection intensified pain. The participants expressed constant fear of infection and this was particularly prominent during the dressing change

procedure, as many believed that their wound was only at risk of infection when it was uncovered: Participant (France) – “It’s excruciating, it’s awful” Participant (UK) – “It never sees the light of day so how does it get infected?”

Participant (Canada) – “You live in fear of getting an infection, you do everything you can and then they say you have an infection and you start the battle all over again”

9>H8JHH>DC It is impossible for patients to forget about their chronic wounds when their everyday life tends to revolve around their condition. The combined effect of persistent woundrelated pain and spontaneous intermittent bursts of intense pain are debilitating and distressing for patients yet, although the participants in this study found it difficult to cope with the unpredictable nature of their pain, they were reluctant to talk about it with friends and family. An insidious progression toward marginalisation and isolation appeared to be a direct result of pain and as a consequence impacted on the participants’ ability to carry out everyday activities. This was amplified by negative physical appearance, odour, uncertainty of the healthcare system, and misunderstanding and fear of infection.

The participants in this study, particularly those in the French group, emphasised feelings of shame about the appearance of their wound/dressings and accentuated that pain led to negative facial expression, subdued body appearance and a reluctance to socialise. Psychological research in the area of body image reinforces the view that attractiveness is valued highly within all societies and that the less conventionally attractive receive less in the way of support from others which can result in a decrease in self esteem and negative self-image17. Furthermore a definite relationship has been observed between depression and negative body image18. Studies of health-related quality of life suggest that patients with chronic conditions adapt over time to their altered lifestyle4, however it would appear that the participants in this study were reluctant to accept their new status in society.

Ineffective treatment of pain is a constant finding in the research19 and never being completely free of pain may have a significant influence on a person’s evaluation of their healthcare in general. This is perhaps enhanced in patients with chronic wounds due to a limited understanding of their condition9, an over-reliance on other people and a tendency to base current perceptions (particularly of the dressing change process) on previous negative experiences.

Yet for some of the participants an unrealistic expecta0

'+

:LB6

Journal 2008 vol 8 no 2

Collagen tissue technology

For 10 years, the Integra Dermal Regeneration Template has provided solutions in : - Burn surgery - Reconstructrive surgery - Chronic wounds - Paediatric

WITH OR WITHOUT SILICONE,

- Traumatology

WE OFFER POSSIBILITIES FOR YOUR TREATMENT

Integra: Regenerating tissue, Rebuilding lives

For more information on Integra products, please visit : www.Integra-LS.com Integra, Integra Dermal Regeneration Template and the Integra wave logo are trademarks or registred trademarks of Integra LifeSciences Corporation. Š2008 Integra LifeSciences Corporation. All rights reserved. ILS 02-503-02-08.

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

tion that pain should be tolerated was preferable to the perceived stigma of becoming reliant on pain relieving medication.

Fear of infection appeared to be a constant source of anxiety among all the participants regardless of cultural background and these feelings were reinforced by inadequate explanation of the cause of infection. There is little evidence of the impact of wound-related pain on factors such as hope and optimism but it could be assumed that constant episodes of unexplained infection and persistent pain would have a negative influence on a person’s emotional health or their ability to maintain an optimistic outlook. Participants in this study were known to have a history of pain, and consequently may not be truly representative of all patients with chronic wounds.

However, research has indicated that substantial numbers of patients report pain as one of the worst aspects of their condition20,21.

8DC8AJH>DC The impact of pain on a person’s life is a multifaceted and individual experience and its overall effect should never be underestimated. Patients’ day to day lives are permanently dictated by their condition which presents a constant reminder that they have a wound. Pain is ever-present and at times can be difficult to tolerate, leading to difficulties in carrying out daily tasks, a reduced feeling of well-being and social isolation. A conflict of interest can exist when the trajectory of patient management is focused on healing yet the patients’ aspirations are to feel pain-free so that they can take up everyday activities once more.

GZ[ZgZcXZh 1. Franks PJ, Moffatt CJ, Connolly M, Bosanquet N, Oldroyd M, Greenhalgh RM, McCollum CN. (1994). Community Leg Ulcer Clinics: Effect on quality of life.

E]aZWdad\n .: 83-86 2. Price P. An holistic approach to wound pain in patients with chronic leg ulceration.

LdjcYh (2005) &, (3): 55-57 3. Ebbeskog B, Ekman SL. Elderly persons’ experiences of living with venous leg ulcer: living in a dialectal relationship between freedom and imprisonment. HXVcY^cVk^Vc ?djgcVa d[ 8Vg^c\ HX^ZcXZ (2001) &*(3): 235-43.

Implications for clinical practice • The impact of pain plays a huge part of the patients’ life.

• Each individual patient’s needs should be recognised and re-evaluated regularly.

• Giving patient’s the opportunity to talk about their pain experiences with others who understand can be extremely comforting.

Further Research • A questionnaire has been developed based on the results from this study and this has been used in an international survey which aimed to collect data on patient’s wound-related pain experiences; from 15 8 countries world-wide.

Potential Conflict of Interest: This work is supported by an unrestricted educational grant from Mölnlycke Health Care.

Acknowledgements: The authors would like to thank the participants, nurses and staff at Hôpital Charles Foix, Ivry-sur-Seine, France, the Wound Healing Research Unit, Cardiff University, Wales, UK and Women’s College Hospital, Toronto, Ontario, Canada.

12. Douglas V. Living with a chronic leg ulcer: an insight into patients’ experiences and feelings. ?djgcVa d[ LdjcY 8VgZ (2001) &% (9): 355-360 13. Krasner D. Painful venous ulcers: themes and stories about living with the pain and suffering. ? LdjcY Dhidbn 8dci^cZcXZ Cjghe (1998) '*(3): 158-68.

14. Ribu L, Hanestad BR, Moum T, Birkeland K, Rustoen T. Health-related quality of life among patients with diabetes and foot ulcers: association with demographic and clinical characteristics. ?djgcVa d[ 9^VWZiZh VcY ^ih 8dbea^XVi^dch. (2007) '&: 227-236.

4. Price P and Harding KG. Measuring Health Related Quality of Life in Patients with Chronic Leg Ulcers. LdjcYh (1996) - (3): 91-94

15. Briggs M, Closs SJ. Patients’ perceptions of the impact of treatments and products on their pain experience of leg ulcer pain. ?djgcVa d[ LdjcY 8VgZ (2006) &* 8): 333-337.

5. Walshe C. Living with a venous leg ulcer: a descriptive study of patients’ experiences. ?djgcVa d[ 6YkVcXZY Cjgh^c\ (1995) '' (6): 1092-100.

16 Stemler S. An overview of content analysis. EgVXi^XVa 6hhZhhbZci GZhZVgX] VcY :kVajVi^dc# , (17): 1-9.

6. Krasner D. The chronic wound pain experience: a conceptual model. Dhidbn VcY LdjcY BVcV\ZbZci (1995) )&(3): 20-35.

17. Newell R. Body-image disturbances: cognitive behaviour formulation and intervention. ?djgcVa d[ 6YkVcXZY Cjgh^c\ (1991) &+: 1400-1405

7. Pieper B and DiNardo E. Reasons for non-attendance for the treatment of Venous Ulcers in an inner-city clinic. ? LdjcY Dhidbn VcY 8dci^cZcXZ Cjgh^c\# (1998) '*(4): 180-6.

18. Noles SW, Cash TF, Winstead BA. Body image, physical attractiveness and depression. ?djgcVa d[ 8dchjai^c\ VcY 8a^c^XVa EhnX]dad\n (1985) *( (1): 88- 94.

8. Noonan L, Burge SM. Venous leg ulcer: is pain a problem? E]aZWdad\n (1998) &(: 14-19.

9. Charles H. ‘The impact of leg ulcers on patients’ quality of life’ Egd[Zhh^dcVa CjghZ (1995) &% (9) : 571-574 10. Hamer, C. Cullum N.A. Roe B.H. Patients’ perceptions of chronic venous leg ulcers. ?djgcVa d[ LdjcY 8VgZ (1994) ( (2): 99-101.

11. Hareendran, A. Bradbury, A. Budd, J. Geroulakos, G. Hobbs, R. Kenkre, J. Simonds, T. Measuring the impact of venous leg ulcers on quality of life. ?djgcVa d[ LdjcY 8VgZ (2005) &) (2): 53-57.

'-

19. Persoon, A. Heinen, M.M. van der Vleuten, C.J.M. de Rooij, M.J. van de Kerkhof, P.C.M. van Achterberg, T. Leg ulcers: a review of their impact on daily life. ?djgcVa d[ 8a^c^XVa Cjgh^c\ (2004) &(: 341-354.

20. Nemeth KA, Harrison MB, Graham ID, Burke S. Pain in pure and mixed aetiology venous leg ulcers: a three phase point prevalence study. ?djgcVa d[ LdjcY 8VgZ (2003) &' (9): 336-340 21. Hofman D, Ryan T, Arnold F et al. Pain in venous leg ulcers. ?djgcVa d[ LdjcY 8VgZ (1997) + (5): 222-224

:LB6

Journal 2008 vol 8 no 2

EXPECT THE MOST

A 10 x 10 cm sorbion sachet S absorbs and binds more than 100 ml!

www.sorbion.com For trial samples and a complete literature pack please contact:

sorbion AG · Hobackestr. 91 · D-45899 Gelsenkirchen T. +49 (0) 209 95 71 88 0 · F. +49 (0) 209 95 71 88 20 · info@sorbion.de

Q The patient gains: Less pain, more comfort, improved quality of life Q The clinician gains: Faster healing means fewer dressing changes, reduced risks of complications, reduced workload and reduced costs

· [[[ SVERKS QW

The innovative sorbion sachet S is our modern way to treat moderate to high exudating wounds with its super absorbent polymers.

Find out more during EWMA at the KCI Booth and at the KCI Symposium ©2007 KCI Licensing, Inc. All Rights Reserved. All trademarks designated herein are property of KCI, its affiliates and licensors. Those KCI trademarks designated with the “®”, “TM” or “*” symbol are registered in at least one country where this product/work is commercialized, but not necessarily in all such countries. Most KCI products referenced herein are subject to patents and pending patents.

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

:[ÃXVXn d[ ]dcZn Vh V YZhadj\]^c\ V\Zci/ overview of current evidence >CIGD9J8I>DC Chronic wounds are characterised by duration, prolonged inflammation, increased risk of infection and are associated with either a local or systemic altered physiological state. Slough is an impediment to healing in these wounds as it provides a stimulus for inflammation, the optimal culture medium for bacterial proliferation, impedes epithelial edge advancement, and impairs visualisation of the wound bed1,2. Additionally it increases exudate production and malodour3.

Many case studies and randomised controlled trials (RCTs) report the efficacy of honey in rapidly removing slough from a variety of wound aetiologies4-10. There is however, variability in the type of honey used and the method of outcome evaluation thus reducing the potential for combined evaluation of efficacy, except in the case of Manuka honey10. This limitation applies to other RCTs which have evaluated the efficacy of topical agents to deslough wounds11-13.

Persistent necrotic tissue in the wound provides a nidus for infection which in turn is associated with the release of bacterial exotoxins into the wound, consequently, inducing a continuous state of early inflammation and preventing the progression onto healing (Himel 1995). Some bacteria produce ammonia which, in itself, is necrotizing and can impair oxygenation of the tissues by raising the pH16.

Alkalinity supports the activity levels of many proteases in wound fluid, consequently promoting degradation of the extracellular matrix (ECM) and key functional molecules such as growth factors of the wound17,18. An elevated alkaline environment, as recorded in chronic wounds is invariability correlated with non-healing19-21.

JC9:GHI6C9>C< HADJ<= Slough is a form of necrotic tissue which is visible on the surface of the wounds as moist, loose, stringy tissue, typically yellow and represents a complex mixture of fibrin, deoxyribonucleo-protein, serous exudate, leucocytes and bacteria14.

This tissue tends to accumulate continually in chronic wounds because such wounds generally result from underlying and uncorrected pathogenic abnormalities such as diabetes mellitus or venous insufficiency1. Slough is related to the inflammatory phase of wound healing when dead cells accumulate in exudate but the body normally keeps pace with the it’s build up through a natural process of autolysis. Autolytic debridement of slough is achieved by the body as it generates an endogenous system capable of natural removal of unwanted material15. During the normal wound healing process leukocytes enter the wounds with removal of devitalised tissue and foreign material15.

A prolonged inflammatory response and the lack of regulation of protease activity in chronic wounds results in degradation of the components of the extra cellular matrix by the same processes that normally have protective and restorative functions, leading to the eventual tissue breakdown, seen in chronic wounds23. This continual breakdown of wound tissue is visible as slough in the wound bed.

It therefore follows that wound healing is delayed in its presence and while many topical treatment options are available for its removal, to date, systematic reviews have concluded that no one agent has demonstrated superior efficacy over another and there are no studies which compare debriding with no debriding24,25. In one systematic review, however, of the management of diabetic there is evidence to suggest that hydrogel increases the healing of diabetic foot ulcers compared with gauze or standard wound care but it is not clear if

:LB6

Journal 2008 vol 8 no 2

Slough and necrotic tissue also cause hypoxia in the wound area which inhibits development of granulation tissue and slows re-epithelization (Konig et al. 2005). Furthermore, migration of lymphocytes and macrophages is hampered in the presence of slough or necrotic tissue12,22.

<Zdg\^cV <Zi]^c PhD, HE Dip Wound healing, RGN, Dip Anatomy, Dip Physiology, Lecturer Research Centre Faculty of Nursing and Midwifery Royal College of Surgeons in Ireland 123 St Stephens Green Dublin 2, Ireland ggethin@rcsi.ie

0

(&

this effect is due to debridement26. Moreover, while there are no studies of debridement versus no debridement it is not clear what percentage of the wound should be covered in slough to significantly affect wound healing.

The advantages to wound healing when wounds are debrided are well documented1,2 and can be summarised into 4 key areas as in Table 1.

IVWaZ &/ 6YkVciV\Zh d[ ldjcY YZWg^YZbZci LdjcY [VXidgh EdiZci^Va djiXdbZ Extent Allows visualisation of full depth and extent of the wound Consequence Reduces the possibility for infection, sepsis, or amputation. Decreases exudate and malodour.

Investigation Allows tissue samples or culture swabs to be taken from depth of wound. Facilitates visualisation of all structures exposed in the wound Outcome Removes impediments to wound healing such as debris, slough, bacteria, and exudate.

=DC:N 6C9 LDJC9 =:6A>C< Honey has been used in wound management for over 4500 years27. Its use declined in the early 1900s with the advent of antibiotics and a move towards ‘modern’ wound treatment options. A renewed interest in its use in wound management in the last two decades is evidenced by increasing numbers of in vitro and in vivo studies within the literature28. However, honey is not a generic entity. The variation in colour, taste, consistency, water content and acidity is due to both the plant species and the foraging bee together with the local climate and soil characteristics29. In vitro studies have investigated the variability in antimicrobial properties, and have demonstrated clear differences in the efficacy of honey as an antibacterial agent with Manuka honey demonstrating efficacy against a wide range of organisms including; Methicillin resistant staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VRE)30-32. Currently, no clinical studies are published in which direct comparison of different honeys used in wounds have been made.

B:I=D9H D; LDJC9 9:7G>9:B:CI There are many excellent texts which outline the options for wound debridement and it would not be prudent to revisit these here. The method used is dependent on the aetiology of the wound, the skills, expertise, knowledge, and resources of the clinician together with patient and clinician treatment goals. The principle mode of action of honey in wound debridement is through autolysis and thus will be explored here.

Autolytic debridement is dependent on the local wound environment, in particular the state of wound hydration; but also the wound temperature, pH and enzymatic co('

factors availability15. Autolytic is the most selective form of debridement, it requires minimal clinical training, is painless and although slow, it leaves a clearly demarcated line between the living and dead tissue15,33. It does however, require at least some level of exudate to be effective15. A limitation of this method is that older populations produce decreased amounts of endogenous proteases, such as collagenase in their wound fluid1. Baherastani2 argues that this resultant decreased production and activity of endogenous collagenase may lead to insufficient debridement of necrotic tissue, decreased deposition of granulation tissue and matrix remodelling as well as decreased proliferation and migration of keratinocytes. A further limitation of this method is that it is not recommended for clinically infected wounds or in those with a high potential for anaerobic infection or if there is ischaemia of the limb or digits2,15,34.

Autolytic debridement occurs to some extent in all wounds, is a highly selective process whereby macrophages phagocytise bacteria and endogenous proteolytic enzymes such as collagenase, elastase, myeloperoxidase liquefy and spontaneously separate necrotic tissue and pseudoeschar from healthy tissue2. The wounds own fluid contains macrophages, and neutrophils that digest and solubilize necrotic tissue33.

=DL =DC:N 8DCIG>7JI:H ID LDJC9 9:7G>9:B:CI Honey is a highly osmolar substance35,36. Colloidal honey has a low osmotic pressure and when applied to wounds, goes through a physiological change37. When in contact with wound tissue, the hygroscopic quality of the honey permits dilution by the tissue fluids, so that the colloidal sugar passes into molecular solution, the osmotic pressure increases and plasmolysis becomes more active37. The high osmolarity supports the outflow of fluid from deep wound tissue to the surface tissue aiding cleansing, debridement and reducing oedema and decreasing pain35,36. Moist dressings (such as honey) allow endogenous enzymes in the wound fluid to liquefy necrotic tissue selectively33.

Chirife et al. (1983) investigated this ‘outflow of fluid’ and concluded that the application of sugar promotes movement of water from an area of high concentration to an area of low concentration thus, contributing to wound cleansing. It is argued that this osmotic pressure could possibly dehydrate delicate new cells in the wound and thus delay healing27. Conversely, Chirife et al. [38] proposed that in living organisms, a flux of water from the inner regions replaces water as fast as it is transferred from the surrounding cells to the wound surface; consequently external tissue remains wet, and the healing process is not adversely affected. Cooper (2001) supports this theory, as :LB6

Journal 2008 vol 8 no 2

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

movement of fluid in response to this osmotic pull leads to improvement in the microcirculation and increased levels of dissolved oxygen and nutrients.

Of all the cells involved in the wound healing process, monocytes are one of the most important as they contribute to the inflammatory phase and play a role in wound debridement. The effect of Manuka, pasture and artificial honey on production of reactive oxygen intermediates (ROIs), and Tissue Necrosis Factor alpha (TNFG) release in human monocytic cells demonstrated a spontaneous release of TNF-G from resting monocytic cells in vitro in the presence of Manuka and pasture honey; but not with artificial honey39. The authors of the latter study suggested that an unidentified component within these honeys may be responsible and that honey modulated the activation of monocytic cells in vitro without affecting viability and this modulation gives inhibitory and stimulatory effects39.

This would suggest that Manuka honey is a stimulus for wound debridement as it supports the cells necessary for this action.

Autolytic debridement is pH sensitive and research has shown that the application of Manuka honey can significantly reduce surface pH of chronic non-healing wounds

over a two week period (p < 0.001)19. Whether this effect would contribute to preventing the build up of slough or facilitate its removal is not clear but a reduction in 0.1 pH unit was associated with an 8.1% reduction in wound size (p < 0.029)19.

The literature records many case studies of honey effectively removing slough from both acute and chronic wounds.

A pilot study using Honeysoft® (Mediprof, The Netherlands) reported on thirteen complex wounds of varying aetiologies which were effectively debrided with reduced exudate, malodour and improved epithelization over three weeks40. This rapid debridement was also achieved when a local honey (Nigerian) was used in the treatment of 43 cases of pyomyositis abscess in children41. Honey was applied daily and the authors reported shorter duration of antibiotic use and hospital study when honey was used.

Other single case studies report rapid debridement of between 2 days and three weeks in a variety of wound aetiologies when honey dressings were used7,9,42. As case studies do not prove a cause and effect relationship and as the types of honey varied between cases, a more robust approach to quantifying efficacy is required. One RCT 0 (described below) addressed this issue10.

Pressured to Prevent Heel Ulcers?

Choose Heelift® Suspension Boot The Pressure-Free Solution Now there’s proof that Heelift® Suspension Boots provide a pressurefree environment to help eliminate the onset of pressure ulcers and to help heal existing ulcers. Using a 16-sensor force sensing pad affixed to the heel of the subject patient, pressure was “mapped” using various pressure reduction products. In all tests, Heelift® provided a pressure-free solution!

Heelift® Suspension Boot

Pressure Reduction Mattress

Heel Protector

Heel Pillow

Heelift® has added design features for more comfort, support and easier, one-handed closure.

• Extended stitching along the top rim narrows the forefoot, increasing support to protect against foot drop, equinus deformity or heel cord contracture • Two non-abrasive, soft straps with D-ring closures permit easy adjustment of strap tension

Darco (Europe) GmbH

Moorings Mediquip

Gewerbegebiet 18 • 82399 Raisting Tel: +49-8807-9228-0 • Fax: +49-8807-9228-22 info@darco-europe.com www.darco-europe.com

Mobility & Independent Living Centre 51 Slaght Road • Ballymena Co Antrim BT42 2JH • N.Ireland Tel: +44 28 2563 2777 • Fax: +44 28 2563 2272 e-mail: sales@mooringsmediquip.co.uk

Heelift® Original and Smooth Patent No. 5449339 Additional patents pending

©2006 DM Systems, Inc.

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc

One hundred and eight patients with venous ulcers in which r 50% of the wound bed was covered in slough were randomly assigned to either Manuka honey dressing or Hydrogel therapy10. Wounds were dressed weekly for four weeks and compression therapy continued in all cases. The performance of both agents was highly clinically significant as the mean wound area covered in slough decreased to 29% in honey group vs 43% in hydrogel (p 0.065). While this was not an equivalence study it does quantify the desloughing efficacy of both agents when slough was the predominant tissue type. This study adds to our body of knowledge as it investigated a specific sub-set of venous ulcers i.e. having > 50% slough in wound bed and quantified the expected healing rates after 12 weeks.

A further important finding in the latter study was that wounds in which >50% slough was removed by week 4 had a greater probability of healing at week 12 (CI 1.92, 9.7, RR 3.3, p 0.029). This supports the expert opinion that removal of slough promotes healing.

Direct comparison of desloughing efficacy of Manuka honey with other studies is limited as slough was not the predominant tissue type in other studies, the method of outcome evaluation was very subjective and the duration of the studies was very short11-13. Based on these studies, honey can be said to be slower than larvae but faster than some hydrogels, enzymatic agents, or hydrocolloids. Future studies investigating desloughing efficacy of topical agents should provide details of how outcomes were evaluated, monitor patients up to 12 weeks and have slough as the predominant tissue type. In so doing, efficacy and impact on healing can be determined.

1 Himel H. Wound Healing: focus on the chronic wound. Wounds. 1995;supp A(5):70A-7A. 2 Baharestani M. The clinical relevance of debridement. Heidelberg: Springer-Verlag 1999.

Foul odour is associated with necrotic tissue and is usually caused by superficial bacterial colonisation. Malodour is distressing for patients and indeed may affect compliance with treatment regimes. Large case series and individual case studies have reported honey as very effective in reducing malodour in chronic sloughy wounds40,43.

To maintain optimal effect of honey as a topical agent, it is recommended that honey should stay in contact with the wound. The ability of honey to maintain wound contact and deslough is influenced by the type of secondary dressing, type of honey dressing used, level of exudate and the frequency of dressing change28. NICE44 guidelines recommend that choice of debriding agent should be based on impact on comfort, odour control and other aspects relevant to patient acceptability. Lewis25 further recommends that selection of debriding agents should be guided by good evidence and cost. Honey and in particular Manuka honey meets many of these requirements although cost benefit analysis of its use as a debriding agent is lacking.

8DC8AJH>DC Honey can be considered as an effective desloughing agent, particularly in chronic wounds. The mode of action while not completely understood, incorporates; natural cleansing through the osmotic pressure it generates at the wound surface; reduction in surface pH thus reducing potential for protease activity; autolytic debridement through maintaining a moist environment; antimicrobial properties which reduces the potential for production of bacterial 8 endotoxins.

11 Colin D, Kurring PA, Quinlan D. Managing sloughy pressure sores. Journal of Wound Care.

1996;5(10):444-6.

3 Dealey C. The care of wounds: a guide for nurses.

3rd ed: Blackwell Publishing 2005.

12 Thomas S, Fear M. Comparing two dressings for wound debridement. Journal of Wound Care.

1993;2(5):272-4.

4 Efem SEE. Clinical observations on the wound healing properties of honey. British Journal of Surgery.

1988;75:679-81.

13 Wayman J, Nirojogi V, Walker A, Sowinski A, Walker M. The cost effectiveness of larval therapy in venous ulcers. Journal of Tissue Viability. 2000;10(3):91-4.

5 Green AE. Wound healing properties of honey. British Journal of Surgery. 1988;75(12):1278.

14 Thomas AM, Harding KG, Moore K. The structure and composition of chronic wound eschar. Journal of Wound Care. 1999;8(6):285-7.

6 Hejase MJ, Simonin JE, Bihrle R, Coogan CL. Genital Fournier’s gangrene: experience with 38 patients.

Urology. 1996;47(5):734-9.

7 Dunford C, Cooper RA, Molan PC. Using honey as a dressing for infected skin lesions. Nursing Times.

2000;96(NTPLUS 14):7-9.

8 Natarajan S, Williamson D, Grey J, Harding KG, Cooper RA. Healing of an MRSA-colonised, hydroxyurea-induced leg ulcer with honey. J Dermatol Treat. 2001;12:33-6.

9 Van der Weyden EA. The use of honey for the treatment of two patients with pressure ulcers. British Journal of Community Nursing. 2003;8(12):S14-20.

10 Gethin G, Cowman S. Manuka honey vs Hydrogel to deslough venous leg ulcers: A Randomised Controlled Trial. Paper presented at 17th EWMA Conference: 2-4 May 2007: Glasgow, UK. EWMA Journal - Supplement, 2007, vol 7, May, p 28.

()

15 Ayello E, Cuddigan J. Debridment: controlling the necrotic/cellular burden. Advances in skin and wound care. 2004;17(2):66-75.

16 Leveen H, Falk G, Borek B, Diaz C, Lynfield Y, Wynkoop B, et al. Chemical acidification of wounds An adjuvant to healing and the unfavourable action of alkalinity and ammonia. Annals Surgery. 1973 December;178(6):745-50.

17 Greener B, Hughes A, Bannister N, Douglass J. Proteases and pH in chronic wounds. Journal of Wound Care. 2005;14(2):59-61.

18 Trengove N, Stacy M, Maculey S, Bennett N, Gibson J, Burslem F, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair and Regeneration. 1999 November-December;7:442-52.

19 Gethin G, Cowman S. Change in pH of chronic wounds when a honey dressing is used. International Wound Journal. 2007;in press.

20 Tsukada K, Tokunaga K, Iwama T, Mishima Y. The pH changes of pressure ulcers related to the healing process of wounds. Wounds: a compendium of clinical research and practice. 1992;4(1):16-20.

21 Romanelli M, Schipani E, Piaggesi A, Barachini P. Evaluation of surface pH on venous leg ulcers under Allevyn dressings. London: The Royal Society of Medicine Press 1997.

22 Morrison M, Moffatt C. A Colour Guide to the Assessment and Management of Leg Ulcers. 2nd ed.

London: Mosby 1994.

23 Schultz G, Mozingo D, Romanelli M, Claxton K. Wound healing and TIME: new concepts and scientific applications. Wound Repair and Regeneration.

2005;13(4):S1-S11.

24 Bradley M, Cullum N, Sheldon T. The debridement of chronic wounds: A systematic review. Health Technology Assessment. 1999 September 1999;3(17 Pt 1).

25 Lewis R, Whiting P, ter Riet G, O’Meara S, Glanville J. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention. Health Technology Assessment. 2001;5(14).

26 Smith J. Debridement of diabetic foot ulcers. The Cochrane database of systematic reviews 2002:Art. No. CD003556. DOI: 10.1002/14651858.

27 Forrest R. Early history of wound treatment1. Journal of Royal Society of medicine. 1982 March;75:198205.

:LB6

Journal 2008 vol 8 no 2

Drinaghan, Knocknarea, Sligo, Ireland /WG

To: President, European Wound Management Association Re: Research Grant Date: 22/04/2007 Dear Prof Vowden, In 2003 I was the proud recipient of a research grant from EWMA at the conference in Pisa, Italy. This grant of `10,000 was made towards my research on the use of Manuka honey in venous ulceration.

As a consequence of this grant I was able to continue with my studies which up to that point has been completed without funding. Following this, I applied to the Health Research Board of Ireland for a clinical research fellowship in nursing and midwifery and was granted this in 2004. The international review process for this application recognised the grant aid that was already received. The research board recommended that my studies continue to PhD which they would fund accordingly.

After almost 5 years of study the RCT which compared Manuka honey to a standard agent to deslough venous ulcers will be presented for the first time at the EWMA conference in Glasgow. Throughout the course of my studies I have completed other research on wound measuring, wound pH and wound assessment, and again I have presented these through EWMA conference and journal.

In each publication and in each presentation I have been proud to acknowledge the grant aid from EWMA and wish to thank you for the contribution this organisation has made to my studies and career. On my return to Ireland from Glasgow I look forward to finalising and submitting my PhD thesis.

Thanking you again

28 Molan P. The evidence supporting the use of honey as a wound dressing. Lower Extremity Wounds.

2006;5(1):40-54.

29 White JW, Doner LW. Honey composition and properties. Beekeeping in the United States agricultural handbook number 335. 1980 October.

30 Cooper R, Molan P, Harding KG. Antibacterial activity of honey against strains of Staphylococcus aureus from infected wounds. Journal of Royal Society of Medicine. 1999;92:283-5.

<Zdg\^cV <Zi]^c

37 Seymore F, West F. Honey - its role in medicine.

Medical Times. 1951;79(2):104-7.

38 Chirife J, Herszage L, Joseph A, Kohn E. In vitro study of bacterial growth inhibition in concentrated sugar solutions; Microbiological basis for the use of sugar in treating infected wounds. Antimicrobial Agents and Chemotherpy. 1983;23(5):766-73.

40 Ahmed A, Hoekstra M, Hage J, Karim R. Honeymedicated dressing: transformation of an ancient remedy into modern therapy. Annals of Plastic Surgery. 2003;50(2):143-8.

32 French V, Cooper R, Molan P. The antibacterial activity of honey against coagulase-negative staphylococci. Journal of Antimicrobial Chemotherapy.

2005;56:228-31.

41 Okeniyi J, Olubanjo O, Ogunlesi T, Oyelami O. Comparison of healing in incised abscess wounds with honey and EUSOL dressing. The Journal of Alternative and Complementary medicine. 2005;11(3):5113.

33 Sieggreen M, Malkebust J. Debridement: choices and challenges. Advances in wound care. 1997;10(2):327.

42 Gray D. Mesitran Ointment Case Studies. Wounds Uk Honey Supplement. 2005;1(3):32-5.

34 Davies P. Current thinking on the management of necrotic and sloughy wounds. Professional Nurse.

2004;19(10):34-6.

43 Dunford CE, Hanano R. Acceptability to patients of a honey dressing for non-healing venous leg ulcers.

Journal of Wound Care. 2004;13(5):193-7.

35 Thomas S. Functions of a wound dressing in: Wound Management and Dressings. London: The Pharmaceutical Press. 1990.

44 NICE. Guidance on the use of debriding agents and specialist wound care clinics for difficult to heal surgical wounds. National Institute for Clinical Excellence, Technology Appraisal Guidance -No 24. 2001(24).

:LB6

Journal 2008 vol 8 no 2

Pioneering Novel Wound Healing Approach Polyheal Ltd. is pioneering a revolutionary wound management approach by filling the unmet need in the wound-care market with a general stimulator of granulation, a major step in the healing process of acute and chronic wounds Polyheal's wound-healing approach has shown a high rate of complete healing or wound improvement for skin grafts and a wide range of chronic wounds which were incurable by conventional treatments.

Our wound-care products are easily applied by the caregiver or patient and significantly reduce the hospitalization period and treatment costs.

39 Tonks A, Cooper RA, Price AJ, Molan PC, Jones KP. Stimulation of TNF-alpha release in monocytes by honey. Cytokine. 2001;14(4):240-2.

31 Cooper R, Molan P, Harding KG. The sensitivity of honey to Gram-positive cocci of clinical significance isolated from wounds. Journal of Applied Microbiology. 2002;93(5):857-63.

36 Cooper RA. How does honey heal wounds? In: Munn P, Jones R, eds. Honey and Healing. United Kingdom: International Bee Research Association. 2001.

MICROSPHERES FOR MEDICINE & BIOTECHNOLOGY

www.polyheal.co.il (*

:7LB

ABSTRACTS OF RECENT COCHRANE REVIEWS Publication in The Cochrane Library Issue 2, 2008:

K^iVb^c 8 [dg egZkZci^c\ VcY igZVi^c\ iZiVcjh [Review]

HVaan 7Zaa"HnZg, MSc Review Group Co-ordinator Cochrane Wounds Group Department of Health Sciences Area 2 Seebohm Rowntree Building University of York York, United Kingdom sembs1@york.ac.uk

=Zb^a~ =! @d^kjaV II I]Z 8dX]gVcZ 9ViVWVhZ d[ HnhiZbVi^X GZk^Zlh To be published in Issue 2, 2008 Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd./ 67HIG68I 7VX`\gdjcY/ Tetanus is a severe infection that can be prevented by vaccination. In developing countries vaccination coverage is not always high and in developed countries cases may still occur, particularly in elderly people owing to their reduced immunoprotection. It has been estimated that there are about one million cases of tetanus per year globally. In animal studies, vitamin C protected against various infections.

In a study with rats, vitamin C protected against tetanus toxin.

DW_ZXi^kZh/ To assess the prophylactic and therapeutic effect of vitamin C in tetanus.

HZVgX] higViZ\n/ We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2007, issue 4), MEDLINE (1950 to January 2008), EMBASE (1980 to 2008 Week 03), the Cochrane Wounds Group Specialised Register (January 2008), the Cochrane Infectious Diseases Group Specialised Register (June 2007), and the reference lists of relevant reviews and monographs.

HZaZXi^dc Xg^iZg^V/ We included controlled trials of vitamin C as a prevention or treatment for tetanus, whether or not placebo controlled, in any language, published or unpublished. Two authors independently made inclusion decisions.

9ViV XdaaZXi^dc VcY VcVanh^h/ Both review authors independently extracted data from trial reports.

BV^c gZhjaih/ One single trial was eligible for inclusion.

This non randomised, controlled, unblinded treatment trial involved 117 tetanus patients and was undertaken in Bangladesh. Vitamin C at a dosage of 1 g/day was administered intravenously alongside conventional treatment. At recruitment, the participants were stratified into two age groups and the results were reported by age. In the children aged 1 to 12 years (n = 62), vitamin C treatment was associated with a 100% reduction in tetanus mortality (95% confidence interval from -100% to -94%). In people aged 13 to 30 years

(n = 55), vitamin C treatment was associated with a 45% reduction in tetanus mortality (95% confidence interval from -69% to -5%).

6ji]dgh¼ XdcXajh^dch/ A single, non randomised, poorly reported trial of vitamin C as a treatment for tetanus suggests a considerable reduction in mortality.

However, concerns about trial quality mean that this result must be interpreted with caution and vitamin C cannot be recommended as a treatment for tetanus on the basis of this evidence. New trials should be carried out to examine the effect of vitamin C on tetanus treatment.

EaV^c aVc\jV\Z hjbbVgn/ Tetanus is a disease caused by tetanus toxin, which is produced by the bacterium Clostridium tetani. This bacterium typically infects penetrating wounds contaminated by foreign material such as soil. In developing countries, poor hygiene after childbirth may cause tetanus in newborn babies.

Even though vaccination has dramatically decreased the burden of tetanus, there are still about one million cases per year globally. We found one controlled trial that examined whether 1 gram per day of intravenous vitamin C would help in the treatment of tetanus patients. Vitamin C was used alongside standard treatments for tetanus. Intravenous vitamin C reduced mortality of children aged between 1 and 12 with tetanus by 100% and mortality of 13 to 30 year old patients by 45%. The trial was not properly conducted and therefore great caution is required in the interpretation of the findings. Vitamin C cannot be recommended as a treatment for tetanus on the basis of this single study. Further investigation of the role of vitamin C in tetanus treatment is warranted.

>ciZgb^iiZci ecZjbVi^X XdbegZhh^dc [dg igZVi^c\ kZcdjh aZ\ jaXZgh [Updated Review] CZahdc :6! BVc^ G! KdlYZc @ I]Z 8dX]gVcZ 9ViVWVhZ d[ HnhiZbVi^X GZk^Zlh To be published in Issue 2, 2008 Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd./ 67HIG68I 7VX`\gdjcY/ Intermittent pneumatic compression (IPC) is a mechanical method of delivering compression to swollen limbs that can be used to treat venous leg ulcers and limb swelling due to lymphoedema.

This review analyses the evidence for the effectiveness of IPC as a treatment for venous leg ulcers.

0

(+

:LB6

Journal 2008 vol 8 no 2

We call it QuadraFoam because “Healing-Cleansing-AbsorbingMoisturising-Comfortable-EasyFast-Acting Dressing” just didn’t seem as catchy. ®

QuadraFoam. The first 4-in-1 dressing formulation.

PolyMem, the only QuadraFoam dressing, simplifies your work and improves healing by effectively cleansing, filling, absorbing, and moistening wounds throughout the healing continuum. Finally, a dressing that lives up to its name.

Visit booth Q1 at EWMA and booth 1313 at WUWHS to receive a complimentary case study along with a set of PolyMem samples.

Find your local distributor at www.PolyMem.eu.

www.PolyMem.eu PolyMem and QuadraFoam are trademarks of Ferris Mfg. Corp., registered or pending in the US Patent and Trademark Office and in other countries. © 2008 Ferris Mfg. Corp. All rights reserved. 16W300 83rd St., Burr Ridge, IL 60527 MKL-218,0706

:7LB

DW_ZXi^kZh/ To determine whether IPC increases the healing of venous leg ulcers. To determine the effects of IPC on health related quality of life of venous leg ulcer patients.

HZVgX] higViZ\n/ We searched the Cochrane Wounds Group Specialised Register (December 2007); the Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library Issue 4, 2007; Ovid MEDLINE - 2006 to November Week 2 2007; Ovid EMBASE - 2006 to 2007 Week 49 and Ovid CINAHL - 2006 to December Week 1 2007.

HZaZXi^dc Xg^iZg^V/ Randomised controlled studies either comparing IPC with control (sham IPC or no IPC) or comparisons between IPC treatment regimens, in venous ulcer management were included.

9ViV XdaaZXi^dc VcY VcVanh^h/ Data extraction and assessment of study quality were undertaken by one author and checked by a second.

BV^c gZhjaih/ Seven randomised controlled trials (including 367 people in total) were identified. Only one trial reported both allocation concealment and blinded outcome assessment.

In one trial (80 people) more ulcers healed with IPC than with dressings (62% vs 28%; p=0.002). Four trials compared IPC with compression against compression alone. The first of these trials (45 people) found increased ulcer healing with IPC plus compression than with compression alone (relative risk for healing 11.4, 95% Confidence Interval 1.6 to 82). The remaining three trials (122 people) found no evidence of a benefit for IPC plus compression compared with compression alone. One small trial (16 people) found no difference between IPC (without additional compression) and compression bandages alone. One trial compared different ways of delivering IPC (104 people) and found that rapid IPC healed more ulcers than slow IPC (86% vs 61%; log rank p=0.003).

6ji]dgh¼ XdcXajh^dch/ IPC may increase healing compared with no compression, but it is not clear whether it increases healing when added to treatment with bandages, or if it can be used instead of compression bandages. Rapid IPC was better than slow IPC in one trial. Further trials are required to determine whether IPC increases the healing of venous leg ulcers when used in modern practice where compression therapy is widely used.

EaV^c aVc\jV\Z hjbbVgn/ Venous leg ulcers (open sores) can be caused by a blockage or breakdown in the veins of the leg.

Compression, using bandages or hosiery (stockings), can help heal ulcers. However, they do not always work, and some people are not willing or able to wear them. Intermittent pneumatic compression (IPC) uses an air pump to inflate and deflate an airtight bag wrapped around the leg. This technique is also used to stop blood clots developing during surgery. However, the review of trials found conflicting evidence about whether or not IPC is better than compression bandages and hosiery. Intermittent pneumatic compression (IPC) is better for healing leg ulcers than no compression but it is uncertain if it improves healing when bandages or hosiery are already used.

(-

Ide^XVa cZ\Vi^kZ egZhhjgZ [dg igZVi^c\ X]gdc^X ldjcYh [Updated Review] JWW^c` 9I! LZhiZgWdh H?! :kVch 9! AVcY A! KZgbZjaZc =/ I]Z 8dX]gVcZ 9ViVWVhZ d[ HnhiZbVi^X GZk^Zlh To be published in Issue 2, 2008 Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd./ 6WhigVXi/ 7VX`\gdjcY/ Chronic wounds mainly affect the elderly and those with multiple health problems. Despite the use of modern dressings, some of these wounds take a long time to heal, fail to heal, or recur, causing significant pain and discomfort to the person and cost to health services. Topical negative pressure (TNP) is used to promote healing of surgical wounds by using suction to drain excess fluid from wounds.

DW_ZXi^kZh/ To assess the effects of TNP on chronic wound healing.

HZVgX] higViZ\n/ For this second update of this review we searched the Cochrane Wounds Group Specialised Register (December 2007), The Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library Issue 4, 2007, Ovid MEDLINE - 1950 to November Week 2 2007, Ovid EMBASE - 1982 to 2007 Week 50 and Ovid CINAHL - 1980 to December Week 1 2007.

In addition, we contacted authors, companies, manufacturers, and distributors to identify relevant trials and information.

HZaZXi^dc Xg^iZg^V/ All randomised controlled trials which evaluated the effects of TNP on people with chronic wounds.

9ViV XdaaZXi^dc VcY VcVanh^h/ Selection of the trials, quality assessment, data abstraction, and data synthesis were done by two authors independently. Disagreements were solved by discussion.

BV^c gZhjaih/ Two trials were included in the original review.

A further five trials were included in this second update resulting in a total of seven trials involving 205 participants.

The seven trials compared TNP with five different comparator treatments. Four trials compared TNP with gauze soaked in either 0.9% saline or Ringer’s solution. The other three trials compared TNP with hydrocolloid gel plus gauze, a treatment package comprising papain-urea topical treatment, and cadexomer iodine or hydrocolloid, hydrogels, alginate and foam. These data do not show that TNP significantly increases the healing rate of chronic wounds compared with comparators.

Data on secondary outcomes such as infection rate, quality of life, oedema, hospitalisation and bacterial load were not reported.

6ji]dgh¼ XdcXajh^dch/ Trials comparing TNP with alternative treatments for chronic wounds have methodological flaws and data do demonstrate a beneficial effect of TNP on wound healing however more, better quality research is needed.

EaV^c aVc\jV\Z hjbbVgn/ Topical negative pressure (TNP) therapy is the application of negative pressure across a wound to aid wound healing. The pressure is thought to aid the drainage of excess fluid, reduce infection rates and increase localised blood flow. TNP is also known as vacuum assisted closure (VAC) and sealed surface wound suction. Seven trials compared TNP with either moistened gauze dressings or other topical agents and found no difference in effects. One very small, poor quality trial (7 wounds) showed a reduction in wound volume and depth in favour of TNP. There is no valid or reliable evidence that topical negative pressure increases chronic wound healing.

:LB6

Journal 2008 vol 8 no 2

(2,.(9< '3(44,0*4 %(0(;5 )31/ $)(5$&< $ 2$5(05(' 41)5 4,.,&10( $'+(4,7( 5(&+01.1*: 5+$5 &10)13/4 51 (7(3: &3(7,&( 1) 5+( 4-,0 !+,4 5(&+01.1*: 4($.4 5+( 8160' /$3*,04 23(7(05,0* (96'$5( )31/ 423($',0* 1051 5+( 4633160',0* 4-,0 &$64,0* /$&(3$5,10

1/(5,/(4 5+( *(05.(45 516&+ ,4 5+( /145 $4463(' $)(5$& 5(&+01.1*: ,4 $.41 5+( 3($410 8+: 2$5,(054 64,0* (2,.(9 '3(44,0*4 )((. 4,*0,; &$05.: .(44 2$,0 10 '3(44,0* 3(/17$. !+,4 &1/%,0(' 8,5+ (9&(..(05 ).6,' /$0$*(/(05 /$-( 5+( (2,.(9 3$0*( $0 ())(&5,7( 8160' &$3( /$0$*(/(05 &+1,&( 5 4 0,&( 51 %( *(05.( 5 4 (7(0 0,&(3 51 %( 463(

#+,5( 7,'(0&( )13 $53$6/$5,& 41)5 4,.,&10( 8160' '3(44,0* 64( #160'4 "

#+,5( #160'4 " 71. 01

!+( =.0.:&-( ($.5+ $3( 0$/( $0' .1*1 $0' (2,.(9< $3( 3(*,45(3(' 53$'(/$3-4 1) =.0.:&-( ($.5+ $3( =.0.:&-( ($.5+ $3( 26%. 19

=5(%13* 8('(0 +10(

888 /1.0.:&-( &1/

Wound Dressings

:LB6

LdgaY Jc^dc d[ LdjcY =ZVa^c\ HdX^ 9dj\aVh BXFjZZc

T

he third meeting of the World Union of Wound Healing Societies is truly a partnership between wound care associations (including EWMA), wound care publishers and also industry.

As individuals we all participate, in one way or another, in the creation and dissemination of knowledge in the field of wound care. All share the common problem of treating wounds and together provide a unified voice to ensure the development of wound care as a clinical specialty.

That is “One Problem – One Voice”.

Congress 2008 provides a forum for the dissemination of evidence informed practice on a global basis. The primary goal of Congress 2008 is to present the wound care evidence base and transfer the knowledge, skills, and attitudes for improved patient outcomes.

Treating acute and chronic wounds is an ongoing challenge for health care professionals in all corners of the world. Social, economic, and technological differences, however, can create a vast divide in global approaches to wound care.

Congress 2008 embraces the multicultural, multidisciplinary nature of its audience and provides an opportunity not only to network but also to work together for the benefit of all wound healers on a global basis. This will be accomplished through a preconference day, three plenary sessions, and 10 concurrent streams each with 100 educational sessions.

A web-based initiative, established prior to this Congress, facilitating a review and appraisal of the wound care evidence, resulted in concise evidence statements and this evidence has been

6C >CI:GK>:L L>I= I=: 8=6>G D; I=: LDGA9 JC>DC 8DC<G:HH '%%Dr. Gary Sibbald, president-elect of the World Union of Wound Healing Societies (WUWHS) and chair of the third meeting, discusses the innovative structure of the meeting with the International Wound Journal.

Q: What is unique and innovative about the third congress of the WUWHS? GS: The organising principle of the Toronto 2008 meeting is the evaluation of the evidence base in wound care, which will be considered in the context of efficacy, efficiency and effectiveness to form a framework for best clinical practice. The synthesis of these three major pillars of evidence-informed practice will provide clinicians with a new and comprehensive way of reviewing their practice and ensuring their care is patient focused Q: How does the scientific program support this innovative design?

GS: The scientific program is divided into streams that provide an in-depth review of a range of clinical

)%

problems. The keynote addresses will echo the importance of evidence and patient care. An expert panel will discuss the clinical significance of evidence-based medicine; Stephen Lewis will examine healthcare systems, advocacy and AIDS in Africa; and Marla Shapiro, MD, will focus on life/work balance and her own experiences. The closing plenary session will present highlights from each stream, and provide participants with a congress overview.

Toronto 2008 also takes a pioneering approach to evidence, choosing to evaluate evidence quality according to the type of information, from guidelines to preclinical data. This methodology allows a broader range of knowledge to be considered in developing a clinical strategy, and it is being used in the development of a comprehensive set of evidence-based summaries on all major topics in wound care. These summaries provide clinicians with rapid access to up-to-date practical information in a quick and easy Web-based format.

:LB6

Journal 2008 vol 8 no 2

Zi^Zh 8dc\gZhh '%%This is not a one-time effort! Through a continued partnership with our Platinum Sponsors this will be an ongoing initiative for the World Union. Under the stewardship of Professor R. Gary Sibbald, during his tenure as President, the initiative will be a legacy of the WUWHS. This is not the end, merely the beginning!

As a global community of wound care specialists, we need to share our insights, data, and awareness of common wound care concerns and solutions. When we do this, we can build new initiatives to advance wound care practices and to improve patient outcomes globally. The following is the perspective of the Chair of the Congress.

GZ\^hiZg cdl id eVgi^X^eViZ ^c i]^h \gdjcY"WgZV`^c\ Xdc\gZhh lll#ljl]h'%%-#Xdb

:A:8IGDC>8 HJEEA:B:CI B6N '%%KdajbZ CjbWZg ' BVn '%%EjWa^h]ZY Wn :jgdeZVc LdjcY BVcV\ZbZci 6hhdX^Vi^dc

67HIG68IH

proliferated throughout the meeting in a logical, easy-tofollow agenda.

:LB6'%%- Æ &)"&+ B6N Æ A>H7DC Æ EDGIJ<6A

18th Conference of the European Wound Management Association

LdjcY BVcV\ZbZci • LdjcY =ZVa^c\ · GZhedch^W^a^in VcY 6Xi^dch LLL#:LB6#DG<$:LB6'%%Organised by the European Wound Management Association in cooperation with the Portuguese Wound Management Associations APTFeridas and GAIF

Q: To which healthcare professionals will this congress be of interest?

GS: Toronto 2008 is being hosted by the University of Toronto, with the active participation of the following co hosting groups: the Canadian Association of Wound Care, Canadian Association of Enterostomal Therapists, Registered Nurses Association of Ontario, National Pressure Ulcer Advisory Panel, and American Professional Wound Care Association. The scientific program will be relevant to all clinicians irrespective of professional background , researchers, and teachers working in the field of wound healing and tissue repair caring for patients with wounds of all aetiologies.

I]Z BVn '%%- ZY^i^dc d[ i]Z :LB6 ?djgcVa :aZXigdc^X HjeeaZbZci Xdch^hih d[ Vaa i]Z VXXZeiZY VWhigVXih [dg i]Z :LB6 '%%- 8dc[ZgZcXZ ^c A^hWdc#

>i ^h Y^k^YZY ^cid &)% DgVa egZhZciVi^dch VcY (,+ EdhiZg egZhZciVi^dch VcY ^i ^h edhh^WaZ id YdlcadVY ^cY^k^YjVa VWhigVXih Vh lZaa Vh i]Z Zci^gZ hjeeaZbZci ^cXajY^c\ Vaa i]Z VWhigVXih Vi lll#ZlbV#dg\

Q: What’s next for the WUWHS? GS: Toronto 2008 is a key step in building the WUWHS as an international association. After the congress, we will focus on disseminating the educational toolkits developed at the meeting and sharing expertise between associations.

LLL#:LB6#DG< :LB6

Journal 2008 vol 8 no 2

:LB6 Journal Previous Issues

KdajbZ -! cd &! ?VcjVgn '%%- EgdWaZb Ygj\ ^c_ZXi^c\/ LdjcY XVgZ! ]Vgb gZYjXi^dc VcY hdX^Va ^beVXi 6c\ZaV 9 <j^aY AVgkVa i]ZgVen ^c i]Z igZVibZci d[ Y^VWZi^X [ddi ldjcYh ¡ 6 gZk^Zl d[ i]Z a^iZgVijgZ ;gVc` A 7dla^c\ De^c^dc e^ZXZ/ LdjcY ]ZVa^c\ ^c ]di Xa^bViZh IZgZcXZ ? GnVc 9ZkZade^c\ gZhZVgX] XVeVX^in VcY XVeVW^a^in ^c h`^c WgZV`Ydlc ?^b 9^X` KdajbZ ,! cd (! DXidWZg '%%, KVXjjb Vhh^hiZY XadhjgZ [dg X]gdc^X ldjcYh/ V gZk^Zl d[ i]Z Zk^YZcXZ :# 6cYgZV CZahdc <ZcZgVa egVXi^i^dcZg hjeedgi id XVgZ ]dbZh/ XdaaVWdgVi^dc l^i] V i^hhjZ k^VW^a^in cjghZ heZX^Va^hi VcY egZhXg^W^c\ hjeedgi e]VgbVX^hi AnccZ LVigZi! GVX]Za 7gjXZ >ciZ\gViZY hnhiZb d[ X]gdc^X ldjcY XVgZ ]ZVa^c\ ¡ XgZVi^c\! bVcV\^c\ VcY Xdhi gZYjXi^dc =Z^co ?# ?VcÂ&#x203A;Zc! GdaVcY 7ZX`Zg <j^YZa^cZh [dg i]Z bVcV\ZbZci d[ eVgi^Va"i]^X`cZhh Wjgch ^c \ZcZgVa ]dhe^iVa"gZXdbbZcYVi^dc d[ V :jgdeZVc ldg`^c\ eVgin 7_VgcZ 6ahW_Šgc! 6ccZaZV 7jcioZc 9^VWZi^X ;ddi JaXZg ¡ ;gdb ;^Xi^dc id BVcV\ZbZci# I]Z YZkZadebZci d[ \adWVa \j^YZa^cZh ?Vc 6eZafk^hi! @VgZa 7V``Zg! <Zgad[ 9 KVa` LdjcY =ZVa^c\ ^c BZY^ZkVa :c\aVcY 8Vgda 9ZVaZn 9ZkZadebZci d[ 8a^c^XVa EgVXi^XZ <j^YZa^cZ dc EgZhhjgZ JaXZgh @Vig^Zc KVcYZglZZ KdajbZ ,! cd '! BVn '%%,

>h ^i hV[Z id jhZ hVa^cZ hdaji^dc id XaZVc ldjcYh4 ?d d 8# ;# <djkZ^V! 8g^hi^cV ># B# B^\jÂ&#x201A;ch!

8Â&#x201A;a^V A# H# Cd\jZ^gV! BVgiV ># E# 6akZh I]Z Xdhi d[ egZhhjgZ jaXZgVi^dc EZiZg ? ;gVc`h :e^YZb^dad\n d[ ldjcYh igZViZY ^c 8dbbjc^in HZgk^XZh ^c Edgij\Va :aV^cZ E^cV >begdk^c\ ldjcY VhhZhhbZci i]gdj\] i]Z egdk^h^dc d[ Y^\^iVa XVbZgVh VXgdhh V Eg^bVgn 8VgZ Igjhi 6a^hdc =de`^ch I]Z jhZ d[ iZaZbZY^X^cZ ^c ldjcY XVgZ Gda[ ?ZacZh AdgY ?dhZe] A^hiZg/ i]Z g^hZ d[ Vci^hZei^X hjg\Zgn VcY i]Z bdYZgc eaVXZ d[ Vci^hZei^Xh ^c ldjcY XVgZ 9Vk^Y AZVeZg KdajbZ ,! cd &! ?VcjVgn '%%,

HZa["XVgZ VXi^k^i^Zh d[ kZcdjh aZ\ jaXZg eVi^Zcih ^c ;^caVcY HVaaV HZee~cZc Hbd`^c\ ^h cdi XdcigV"^cY^XViZY ^c bV\\di YZWg^YZbZci i]ZgVen ^c i]Z X]gdc^X ldjcY EVhXVa HiZZckddgYZ :[[ZXi^kZcZhh d[ cdc"VaXd]da Ă&#x201E;ab [dgb^c\ h`^c egdiZXidg dc i]Z h`^ch ^haZh ^ch^YZ i]Z jaXZgh VcY i]Z ]ZVa^c\ gViZ d[ kZ" cdjh aZ\ jaXZgh IVc_V EaVc^chZ` GjX^\V_ LdjcY bZVhjgZbZci/ i]Z Xdcig^Wji^dc id egVXi^XZ <Zdg\^cV I# <Zi]^c >begdk^c\ ZYjXVi^dc ^c ldjcY XVgZ/ Xgdhh^c\ i]Z WdjcYVg^Zh d[ ^ciZgegd[Zhh^dcVa aZVgc^c\ 8Vgda^cZ BX>cidh] LViZg_Zi YZWg^YZbZci d[ YZZe VcY ^cYZiZgb^cViZ YZei] i]ZgbVa ^c_jg^Zh BVnZg IZcZc]Vjh

International Journals The section on International Journals is part of EWMAâ&#x20AC;&#x2122;s attempt to exchange information on wound healing in a broad perspective.

:c\a^h]

6XiV Kjacdad\^XV kda# +! cd &! BVgX] '%%:[[ZXi d[ G"a^ed^X VX^Y ^c i]Z igZVibZci d[ X]gdc^X ldjcYh l^i] ]neZgWVg^X dmn\Zc i]ZgVen/ bdYjaVi^dc d[ \ZcZh ^ckdakZY ^c Vc\^d\ZcZh^h VcY i^hhjZ gZbdYZaa^c\ 6aaZkV G#! IdbVhZii^ B#! HVgi^c^ 9#! :bVcjZaa^ B#!

7dg\]^ 7#! 9^ 9dcVid ;#! CVhdaZ :# I^hhjZ Zc\^cZZg^c\ ^c eaVhi^X hjg\Zgn# 6 Xa^c^XVa gZk^Zl V[iZg &% nZVgh d[ bZi]dYdad\n Veea^XVi^dc E^ZgVc\Za^ B#! 6hidaĂ&#x192; B#! BVgVoo^ B# Edco^d >#!

7ZgiVc^6#! HXVa^hZ 6# EaViZaZi \Za/ ZkVajVi^dc d[ ^ih gdaZ ^c ldjcY WZY egZeVgVi^dc VcY Xa^c^XVa"fjVa^iVi^kZ VcVa^h^h Edco^d >#! E^ZgVc\Za^ B#! BVgX]Zh^c^ 6#! 8VgWdc^ 6#!

IVaZk^ 9#! <gVhhZii^ A#! EZigjXX^ :#! 7ZgiVc^ 6#! HXVa^hZ 6 I]Z ^bedgiVcXZ d[ bZVhjg^c\ i]Z hjWWVcYV\Z egZhhjgZ VcY i]Z egZhZciVi^dc d[ V cZl bZVhjg^c\ YZk^XZ Bdhi^ <#! GdhhVg^ H# I]Z ZmeZg^ZcXZ d[ V Xa^c^XVa VcY bVcV\ZbZci ig^Va ^c V Y^hig^Xi ^c ;adgZcXZ VgZV 7Zgi^c^ B#! 8]Zaa^c^ ;#! 9Za 8dciZ 8#! ;^a^ee^c^ ;#! Cji^ B#!

EVgVY^hd :#! Idoo^ 8#! ;V\\^dc^ H#

:c\a^h]

6YkVcXZh ^c H`^c LdjcY 8VgZ! kda# '&! 6eg^a '%%lll#VhlX_djgcVa#Xdb 8dY^c\ VcY EVnbZci 8]Vc\Zh [dg E]nh^X^Vch @Vi]aZZc 9# HX]Vjb I]Z HiVijh d[ LdjcY 8VgZ ^c 7gVo^a KZgV AÂ?X^V 8dcXZ^Â d YZ <djkZ^V HVcidh!

7ZVig^o ;Vg^Vh 6akZh NVbVYV! BVg^V =ZaZcV HVciVcV BVcYZaWVjb 6hhZhh^c\ i]Z IdiVa EVi^Zci 8Vi]n I]dbVh =Zhh

Edgij\jZhZ

;Zg^YVh! kda# '! cd '! '%%>ciZgk^Zl l^i] 6gb^cYV 8dhiZ^gV CjghZ VcY ;djcYZg d[ 6EI; IZX]c^XVa 6gi^XaZ ¡ EgZhhjgZ JaXZgh/ 8dhi id i]Z CVi^dc VcY 8dhi id i]Z >cY^k^YjVa EZiZg ;gVc`h IZX]c^XVa 6gi^XaZ ¡ I]ZgVeZji^XVa Edh^i^dc^c\/ EgZkZci^\ EgZhhjgZ JaXZgh 9db^c\dh BVaiV >ck^iVi^dc id i]Z :LB6 '%%BVgXd GdbVcZaa^! ;^cc <diigje! 6c^WVa ?jhi^c^Vcd

HeVc^h]

=ZaXdh '%%-! kda &.! cd & :kVajVi^dc ^c k^igd d[ i]Z egdeZgi^Zh d[ h^m YgZhh^c\h [dg i]Z ]ZVa^c\ lZi Zck^gdcbZcih d[ ZmjYVi^kZ ldjcYh G^jh IVggjZaaV ?! AdeZo 7Zgig{c G >c k^kd ZkVajVi^dc jh^c\ Xdc[dXVa b^XgdhXden d[ egdiZXi^kZ Z[[ZXi d[ cd"hi^c\ WVgg^Zg Ă&#x201E;ab ( B 8Vk^adc dc eZg^ldjcY h`^c HZ\dk^V I! Bdg{c ?6! <dcoVaZo H GZYjX^c\ i]Z Z[[ZXi d[ V YdbZhi^X Wjgc <VgXÂ&#x2020;V <dcoVaZo ;! <V\d ;dgcZaah B! GdYg^\jZo EVabV C! <VoiZaj KVaYÂ&#x201A;h K! <VgX^V 8daaVciZh B6!

GdYg^\jZo 7dXVcZ\gV ?8

I]Z :LB6 ?djgcVah XVc WZ YdlcadVYZY [gZZ d[ X]Vg\Z [gdb lll#ZlbV#dg\

)'

:LB6

Journal 2008 vol 8 no 2

:LB6 ;^cc^h]

=VVkV! cd &! '%%- lll#hjdbZc]VVkVc]d^idn]Y^hinh#Ã LdjcYh d[ G]ZjbVigi]d^Y^i^h EVi^Zcih 6ccV =_ZgeeZ GZXd\c^i^dc VcY BVcV\ZbZci d[ BVa^\cVci LdjcYh I^^cV ?VV`daV 8]VaaZc\^c\ LdjcY BVcV\ZbZci =Zak^ =^ZiVcZc 8]gdc^X LdjcYh VcY EgdWaZbh d[ 8^gXjaVi^dc EZ``V @dgiZhc^Zb^ LdjcY BVcV\ZbZci EgVXi^hZh ^c BViZgc^in VcY <ncZXdad\^XVa LVgYh EVja^^cV K^i^`V^cZc! IZg]^ K~^h~cZc >beaZbZciVi^dc d[ Xg^iZg^Vch [dg YdXjbZciVi^dc d[ ldjcY XVgZ JaaV"BVg^ @^ccjcZc! @V^_V HVgVciV! 6ccZa^ :ch^d EZZg Hjeedgi d[ A^bW 6bejiVi^dc EVi^Zcih! EVgi ( :^aV Ijjiij 8Vc i]Z LdjcYh WZ 8VgZY Wn E]dcZ4 IVg_V HVVg^cZc

:c\a^h]

:c\a^h]

BVa^\cVci ÄWgdjh ]^hi^dXnidbV d[ i]Z bVcY^WaZ ^c i]Z XdciZmi d[ V igVjbVi^X BVg_da^c¼h jaXZg 6a^ =dhhZ^c BZh\VgoVYZ]! GVb^c Bdhidà OVYZ] ;VgV]Vc^!

CVi]Vc^Za IgZ^hiZg :hhZcXZ d[ 8VgZ VcY i]Z egZhhjgZ jaXZg WZcX]bVg` · 6c ZkVajVi^dc ;^dcV 7jiaZg B^c^bVaan ^ckVh^kZ iZX]c^fjZ [dg i]Z hjg\^XVa igZVibZci d[ X]gdc^X dhiZdbnZa^i^h ># H^c\]! C# ;Vhh^VY^h! @# ?dcZh

:c\a^h]

I]Z >ciZgcVi^dcVa ?djgcVa d[ AdlZg :migZb^in LdjcYh kda# ,! cd &! '%%]iie/$$^_aZl#hV\ZejW#Xdb BV_dg 9ZkZadebZcih ^c LdjcY 8VgZ/ 6 8g^i^XVa 6eegV^hVa JlZ Ldaa^cV BZVhjgZbZcih ^c LdjcY =ZVa^c\ K^cXZci ;VaVc\V HZb^cVg GZk^Zl/ LdjcYh VcY 9gZhh^c\h Gdh^cZ kVc YZc 7jaX` 8jggZci IgZVibZci d[ 6XjiZ AdlZg :migZb^in 9ZZe KZcdjh I]gdbWdh^h B^X]VZa E# ?Vc_^\^Vc! 7Vgi :# Bj]h :kVajVi^dc d[ LdjcY"=ZVa^c\ EdiZci^Va d[ E^hdc^V \gVcY^h G#7g/ 6 EgZXa^c^XVa HijYn ^c L^hiVg GVih 9# EgVWj! B# CVee^ccV^! @# EdccjYjgV^! @# EgVW]j BGH6 >c[ZXi^dc ^c AdlZg :migZb^in LdjcYh 7gZZ :Yg^h! ?VbZh ;# GZZY! >>> I]Z AVX` d[ GZa^VW^a^in d[ 8a^c^XVa :mVb^cVi^dc ^c i]Z 9^V\cdh^h d[ LdjcY >c[ZXi^dc/ EgZa^b^cVgn 8dbbjc^XVi^dc I]dbVh :# HZgZcV! ?Vhdc G# =Vc[i! GdWZgi HcnYZg Bjai^Ygj\"GZh^hiVci :ciZgdXdXXjh gV[Äcdhjh [gdb V 9ZXjW^ijh JaXZg/ 6 8VhZ GZedgi K^cXZcod HVk^c^! 6hhjciV BVccV! <^dkVcc^ 9^ 7dcVkZcijgV! 8]^VgV 8ViVk^iZaad! BVgo^V IVa^V! 6cYgZV 7VaW^cdi! ;VW^d ;ZWWd! 9dbZc^Xd 9»6cidc^d ;jhVg^jb hdaVc^ ^c i]Z Edhi"igVcheaVci EVi^Zci/ 6c JcjhjVa ;jc\jh 6gXdi GZ`]V! 6cjebV ?# @^cYd! 6ccVbVaV^ GVk^

HlZY^h]

H g Jik~gYZg^c\ Vk ;aZm^"HZVa ;BH/ Zii hnhiZb [ g ]VciZg^c\ Vk [VZXZh^c`dci^cZch ykZgh~iic^c\ dX] hVbbVc[Viic^c\ 6ccZ =^cY]ZYZ Hk gV k^aa`dg [ g h geVi^ZciZg ^ IVcoVc^V 8]g^hi^cV A^cY]dab ?dY"\VbbVa bZidY ^ cnii a_jh ykZgh~iic^c\ dX] WZVgWZic^c\ Vk 6ccZ =^cY]ZYZ K^kdhiVi EG; EaViZaZi G^X] ;^Wg^c [ g WZ]VcYa^c\ Vk `gdc^h`V h g 7d ?©g\ZchZc! BV\cjh A cYV]a! <jc^aaV AVghhdc! =Vch BdcWZg\ EjahZgVi bdcd`gdbVi^h`i a_jh · `Vc YZi e h`ncYV a~`c^c\Zc Vk [dih g ]dh eVi^ZciZg bZY Y^VWZiZh DkZ 9Z]a^c! H akZ :abhi ]a

<ZgbVc

LjcY BVcV\ZbZci! kda# '! cd '! '%%- :c\a^h] VWhigVXih VgZ VkV^aVWaZ [gdb lll#b]e"kZgaV\#YZ

>ciZgcVi^dcVa LdjcY ?djgcVa! BVgX] '%%-! kda# *! >hhjZ & lll#WaVX`lZaaejWa^h]^c\#Xdb I]Z gZk^h^i d[ '%%) ihjcVb^ ^c I]V^aVcY/ X]VgVXiZg^hi^Xh d[ ldjcYh I]VkVi EgVhVgig^i]V! GVX]ViV Ijc\h^g^eVi! EV^gd_ LVgVX]^i I]Z jhZ d[ bVggdl"YZg^kZY hiZb XZaah id VXXZaZgViZ ]ZVa^c\ ^c X]gdc^X ldjcYh AZZ 8 Gd\Zgh! C^X]daVh ? 7Zk^aVXfjV! 9Vk^Y < 6gbhigdc\ L]Zc l^aa > hZZ ndj V\V^c4 I]Z [ViZ d[ gZhZVgX] ÄcY^c\h [gdb ^ciZgcVi^dcVa ldjcY XVgZ Xdc[ZgZcXZh ?d 8 9jbk^aaZ! :b^an H EZi]Zg^X`! C^X`n 8jaajb AZ\ jaXZgVi^dc ^c Edgij\Va/ fjVa^in d[ a^[Z @Vi^V ;jgiVYd! :aV^cZ E^cV! 8]g^hi^cZ ? Bd[[Vii! EZiZg ? ;gVc`h GVY^di]ZgVen VcY ldjcY ]ZVa^c\ =VgZh] A 9ZkVa^V! AjXn BVchÃZaY I]Z gdaZ d[ i]Z kVXjjb"Vhh^hiZY XadhjgZ i]ZgVen ^c i]Z hVakV\Z d[ kZcdjh Xdc\Zhi^dc d[ i]Z [gZZ ÅVe/ XVhZ gZedgi ;Vi^] Jn\jg! =Vaj` 9jbVc! :gh^c za` g! 7V]Vii^c vZ^` o

:c\a^h]

HZgW^Vc

:LB6

?djgcVa d[ LdjcY 8VgZ! 6eg^a ^hhjZ! kda# &,! cd )! '%%lll#_djgcVad[ldjcYXVgZ#Xdb0 _lX5ZbVe#Xdb 6 hijYn d[ W^dÄab"WVhZY ldjcY bVcV\ZbZci ^c hjW_ZXih l^i] Xg^i^XVa a^bW ^hX]VZb^V G#9# LdaXdii! 9#9# G]dVYh >beVXi d[ VY]Zh^kZ hjg\^XVa iVeZ VcY ldjcY YgZhh^c\h dc i]Z h`^c! l^i] gZ[ZgZcXZ id h`^c hig^ee^c\ @#;# 8jii^c\ 7ZcZÄih d[ ^beaZbZci^c\ V a^c` cjghZ \gdje VXgdhh Wdi] Vc VXjiZ VcY V eg^bVgn XVgZ igjhi 9# :kZg^ii 6 ]da^hi^X VeegdVX] id i]Z bVcV\ZbZci d[ V cZjgdeVi]^X eaVciVg jaXZg H# BX8ajh`Zn! 8# <ddYVn 6c ^c k^igd ZmVb^cVi^dc d[ i]Z Vci^dm^YVci VcY Vci^"^cÅVbbVidgn egdeZgi^Zh d[ WjX`l]ZVi ]dcZn 6#?#?# kVc YZc 7Zg\! :# kVc YZc Ldgb! =#8# FjVg^Zh kVc J[[dgY! H#7#6# =Va`Zh! B#?# =dZ`higV! 8#?# 7Zj`ZabVc E]VhZ ' hijYn d[ V cZl =nYgdÄWZg YgZhh^c\ [dg hjeZgÄX^Va X]gdc^X dg VXjiZ ldjcYh C# ;VjX]Zg! H# :]gaZg! ;# K^c! I# 9j\g

GVcZ! kda# &! cd# '! CdkZbWZg '%%, 6kV^aVWaZ dca^cZ Vi lll#aZXZc_ZgVcV#Xdb :mVb^cVi^dc d[ i]Z XdggZaVi^dc WZilZZc g^h` [VXidgh VcY X]VgVXiZg^hi^Xh d[ i]Z kZcdjh jaXZg VcY ^bea^XVi^dch dc i]Z \gVcjaVi^dc dXXjggZcXZ VcY ]ZVa^c\ i^bZ ?# 9Za^ X Hjg\^XVa igZVibZci d[ i]Z Y^VWZi^X [ddi 8# KjXZi^X! 7# 9ja^ X! ># 9^b^ig^_Zk^ X! C# @VaZo^ X! B# 7jbWVh^gZk^ X! C# BVo^ X! ?# ?ZgZb^ X I^hhjZ VY]Zh^kZ Vh i]Z Vci^W^di^X XVgg^Zg ^c i]Z igZVibZci d[ hjg\^XVa h^iZ ^c[ZXi^dch H# 7dgdk^ X! 9_# OYgVk`dk^ X! 7# 8Va^_V! 7# Eda^ X CjghZ VXi^k^i^Zh ^c egZkZci^dc VcY igZVibZci d[ egZhhjgZ jaXZgh ^c i]Z \Zg^Vig^X YZeVgibZci H#6# B^aji^cdk^ X >bedgiVcXZ d[ i]Z VcZb^V igZVibZci ^c eVi^Zcih l^i] ldjcYh 7# 8Va^_V Hjg\^XVa igZVibZci d[ eVi^Zcih l^i] X]gdc^X kZcdjh ^chj[ÄX^ZcXn VcY adkZg ZmigZb^in kZcdjh jaXZgh 9#?# B^a^ X

Journal 2008 vol 8 no 2

?djgcVa d[ I^hhjZ K^VW^a^in! kda# &,! cd '! '%%- 6kV^aVWaZ dca^cZ Vi lll#hX^ZcXZY^gZXi#Xdb

LdjcY ]ZVa^c\ ^c i]Z XdjghZ d[ i^bZ @# 8]g# B ciZg I]Z jhZ d[ bZY^XVa ]dcZn ^c ldjcY ]ZVa^c\ @# @g \Zg LViZg ÄaiZgZY ^c[gVgZY L>G6 [dg i]Z ^begdkZbZci d[ ldjcY ]ZVa^c\ d[ VXjiZ VcY X]gdc^X ldjcYh <# =d[[bVcc

HXVcY^cVk^Vc

LdjcYh HuG kda#&+! cd &! '%%Hjg\Zgn [dg H^cjh e^adc^YVa^h · ]dl XVc ^i WZ ^begdkZY4 BVgXjh < g\Zc IgZVibZci d[ kZcdjh aZ\ jaXZgh l^i] 6igVjbVc V\ 6ccZ BVg^Z AVghZc! :ahZ A^ccZW_Zg\! ;^cc <diigje :mXZa X]Vc\Zh cjig^i^dc egVXi^XZ ?Zch ;dccZhWZX] >cY^XVidgh bjhi WZ jhZY ^c i]Z bZVhjgZbZci d[ i]Z fjVa^in d[ egZhhjgZ jaXZg igZVibZci VcY egZkZci^dc ?Zch ;dccZhWZX]

)(

:LB6 Corporate Sponsor Contact Data Corporate A

Corporate B LZaXdbZ id :LB6 h ild cZl 7 hedchdgh HVcjlVkZ VcY HncZg\n =ZVai]XVgZ

8dadeaVhi Holtedam 1-3 DK-3050 Humlebæk Denmark Tel: +45 49 11 15 88 Fax: +45 49 11 15 80 www.coloplast.com

8dckVIZX :jgdeZ Harrington House Milton Road Ickenham, Uxbridge UB10 8PU United Kingdom Tel: +44 (0) 1895 62 8300 Fax: +44 (0) 1895 62 8362 www.convatec.com

8dk^Y^Zc 154, Fareham Road PO13 0AS Gosport United Kingdom Tel: +44 1329 224479 Fax: +44 1329 224107 www.covidien.com

?d]chdc ?d]chdc LdjcY BVcV\ZbZci Gargrave North Yorkshire BD23 3RX United Kingdom Tel: +44 1756 747200 Fax: +44 1756 747590 www.jnjgateway.com

@8> :jgdeZ =daY^c\ 7#K# Parktoren, 6th ï¬&#x201A;oor van Heuven Goedhartlaan 11 1181 LE Amstelveen The Netherlands.

Tel: +31 (0) 20 426 0000 Fax: +31 (0)20 426 0097 www.kci-medical.com

Ad]bVcc GVjhX]Zg P.O. BOX 23 43 Neuwied D-56513 Germany Tel: +49 (0) 2634 99-6205 Fax: +49 (0) 2634 99-1205 www.lohmann-rauscher.com

BÂ&#x17D;acanX`Z =ZVai] 8VgZ 6W Box 13080 402 52 Göteborg, Sweden Tel: +46 31 722 30 00 Fax: +46 31 722 34 08 www.molnlycke.com

Hb^i] CZe]Zl Po Box 81, Hessle Road HU3 2BN Hull, United Kingdom Tel: +44 (0) 1482 225 181 Fax: +44 (0) 1482 328 326 www.smith-nephew.com

JhZ i]Z :LB6 ?djgcVa id egdÃ&#x201E;aZ ndjg XdbeVcn 9ZVYa^cZ [dg VYkZgi^h^c\ ^c i]Z DXidWZg '%%- ^hhjZ ^h & 6j\jhi '%%-

))

(B =ZVai] 8VgZ Morley Street, Loughborough LE11 1EP Leicestershire United Kingdom Tel: +44 1509 260 869 Fax: +44 1 509 613326 www.mmm.com

6Xi^kV =ZVai]XVgZ AiY 1 Lancaster Park Newborough Road Needwood Burton on Trent Staffordshire DE13 9PD Tel: +44 (0) 8450 606 707 Fax: +44 (0) 1283 576808 www.activahealthcare.co.uk

7# 7gVjc BZY^XVa 204 avenue du Maréchal Juin 92107 Boulogne Billancourt France Tel: +33 1 41 10 75 66 Fax: +33 1 41 10 75 69 www.bbraun.com

;Zgg^h B[\# 8dge# 16W300 83rd Street Burr Ridge, Illinois 60527-5848 U.S.A. Tel: +1 (630) 887-9797 Toll-Free: +1 (630) 800 765-9636 Fax: +1 (630) 887-1008 www.polymem.com

:LB6

Journal 2008 vol 8 no 2

:LB6

:LB6 Edh^i^dc 9dXjbZci '%%EVja =VgibVcc 6< Paul-Hartmann-Strasse D-89522 Heidenheim Germany Tel: +49 (0) 7321 / 36-0 Fax: +49 (0) 7321 / 36-3636 www.hartmann.info

HVcjlVkZ 6< Kreuzlingerstrasse 5 CH-8574 Lengwil Switzerland Tel: +41 71 6868 900 Fax: +41 71 6868 901 www.sanuwave.com

=VgY"id"]ZVa ldjcYh a holistic approach Editor: Christine Moffatt

HdgW^dc 6< Hobackestraße 91 D-45899 Gelsenkirchen Tel: +49 (0)2 09-95 71 88-0 Fax: +49 (0)2 09-95 71 88-20 www.sorbion.com

HncZg\n =ZVai]XVgZ J@ A^b^iZY Wound Care 1 Western Avenue Matrix Park Buckshaw Village, Chorley Lancashire PR7 7NB United Kingdom Tel: +44 1772 299900 Fax: +44 1772 299901 www.synergyhealthcareplc.com

The seventh European Wound Management Association position document will be launched in May 2008 at the EWMA congress ‘Wound Management · Wound Healing - Responsibility and Actions’, to be held in Lisbon, Portugal, 14-16 May 2008.

The document will be available in English, French, German, Italian and Spanish, and can be downloaded from lll#ZlbV#dg\ It is possible to obtain permission to translate the EWMA Position Documents into other languages.

Please contact EWMA Business Office.

For further details contact MEP Ltd, 53 Hargrave Road, London N19 5SH. www.mepltd.co.uk or EWMA Business Office, Congress Consultants, Martensens Allé 8, 1828 Frederiksberg, Denmark Tel: +45 7020 0305 Fax: +45 7020 0315 ewma@ewma.org

EgZk^djh Edh^i^dc 9dXjbZcih/

AVWdgVid^gZh Jg\d 42 rue de Longvic B.P. 157 21300 Chenôve France Tel: (+33) 3 80 44 70 00 Fax: (+33) 3 80 44 71 30 www.urgo.com

:LB6

Journal 2008 vol 8 no 2

)*

8dc[ZgZcXZh

Conference Calendar Conference

Theme

2008

7th National Australian Wound Management Association Conference

Dreams, Diversity, Disasters

May

SAfW 5th Congress (National) 18th Conference of the European Wound Management Association (EWMA 2008)

Wound Healing – Wound Management – Responsibility and Actions

9th Congress of the European Society for Pediatric Dermatology

7-10

Darwin

Australia

May

8

Morges

Switzerland

May

14-16

Lisbon

Portugal

May

15-17

Athens

Greece

5th EADV Spring Symposium

Dermatology Bridging the Continents

May

22-25

Istanbul

Turkey

WUWHS - 3rd Congress

Wound Care Efficacy, Effectiveness & Efficiency

Jun

4-8

Toronto

Canada

Jun

13-14

Koblenz

Germany

Jun

15-19

Ljubljana

Slovenia

Deutsche Gesellschaft für Wundheilung und Wundbehandlung 17th World Council of Enterostomal Therapists meeting

Stoma care, Wound Management & Incontinence

6th World Congress of the IACD

Jun

18-20

Lisbon

Portugal

Oxford – European Wound Healing Summer School

Different aspects of patient wound management based on therapy innovation and clinical research

Jun

18-21

Oxford

UK

Wound Management Association of Kosova

Training workshop with new Kosova assocation

Jun

23-25

Kosova

ETRS 18th Annual Meeting

Joint Meeting with the Tissue Viability Unit of Malta

Sep

10-12

Malta

Sep

11-13

Lucca

Italy

7th Scientific Meeting of the Diabetic Foot Study Group (DFSG) of the EASD 17th EADV Congress

Sep

17-21

Paris

France

VII Congresso Nazionale AIUC

La terapia dell’ulcera cutanea: “Un ponte tra tradizione e innovazione”

Sep

24-27

Rome

Italy

11th Conference of SEBINKO

The Development of Clinical Validy and Best Practices Requirements

Oct

16-17

Tatabánya

Hungary

2nd World Congress of TeleDermatology

Healty Present and Healthier Future

Oct

16-18

Wounds UK

Nov

5° Congresso Nazionale AISLeC

EBN e Wound Care: Nuove Frontiere

WMAT 3rd National Congress

Chinnai

India

Harrogate

UK

Nov

13-15

Napoli

Italy

Nov

27-29

Cesme, Izmir

Turkey

2009 6th EADV Spring Symposium 19th Conference of the European Wound Management Association

Healing, Education, Learning and Preventing in Wound Care

Apr

23-26

Bucharest

Romania

May

20-22

Helsinki

Finland

Bled

Slovenia

Berlin

Germany

8th Scientific Meeting of the Diabetic Foot Study Group (DFSG) of the EASD

Sep

18th EADV Congress

Oct

7-11

;dg lZW VYYgZhhZh eaZVhZ k^h^i lll#ZlbV#dg\

:LB6 Membership Become a member of the :jgdeZVc LdjcY BVcV\ZbZci 6hhdX^Vi^dc and you will receive EWMA position documents annually and EWMA Journal three times a year.In addition, you will have the benefit of obtaining the membership discount, which is normally 15%, when registering for the EWMA Conferences.

A membership only costs 25 EUR a year.

EaZVhZ gZ\^hiZg Vh V :LB6 bZbWZg Vi

LLL#:LB6#DG<

)+

:LB6

Journal 2008 vol 8 no 2

Dg\Vc^hVi^dch

SEBINKO Hungarian Association for the Improvement of Care of Chronic Wounds and Incontinentia Contact: Dr. Maria Hok hokmaria42@mail.datanet.hu szaniko@chello.hu www.sebinko.hu

&hi VccdjcXZbZci XVaa [dg VWhigVXih &&i] 8dc[ZgZcXZ d[ H:7>C@D IViVW{cnV '%%-# &+"&,# d`i WZg# I]Z YZkZadebZci d[ Xa^c^XVa kVa^Y^in VcY WZhi egVXi^XZh gZfj^gZbZcih

The Hungarian H:7>C@D Association was established in 1996 to improve the care of incontinent patients and people with chronic or non-healing wounds. It is a nationwide, voluntary organisation. In the beginning, its members were mainly nurses, but today it has doctors and whole institutions amongst its members: 180 private and 16 whole staff institutions.

We have developed strong working relationships with the instigators and practitioners of the nationwide consensus. Amongst them one can find professional politicians, members of Parliament, members of medical and nursing colleges, leaders of professional and civil organisations, health industry professionals, universities and practitioners and practicing teams.

Our mission statement is as follows: The aim of the SEBINKO Association is to develop a wide scope nationwide cooperation and consensus in the fields of chronic wound prevention and treatment and the improvement of the treatment of incontinence. This we support by developing, teaching and training scientific methods. We are striving to reach our goals through continuous information flow, the SEBINKO magazine, conferences, correspondence, training programmes, and tenders, together with wide-scale cooperation and professional help. We support the development of planned wound treatment and incontinence treatment programmes developed by institutes and responsible, reliable nursing care in the fields of wound treatment and healing. We put special emphasis on the topic of unified documentation and data processing and the training of institutional coordinators for decubitus and incontinence.

The focus of our consensus is the pressure ulcer: the prevention and treatment of decubitus.

At our 10th Anniversary Conference in 2006 we set out our aims for the following 3 years for our members and association: The development of clinical validity and best practice requirements. To achieve this the most important areas of focus will be the development of everyday practices, continuous evaluation, renewal of the nursing research methods, development of training and evidence research.

As a result of our cooperation in EWMA we are hoping to develop methods and share information to improve the healing of our patients and the motivation of the members of our association.

Our association is consciously supporting the following values of professional help and care in wound management: -reservation or reestablishment of the self-care of patients, -security -pain minimisation -infection-free treatment -cost effectiveness in wound treatment.

EWMA2009 20-22 May Helsinki · Finland

Organised by the European Wound Management Association in cooperation with the Finnish Wound Care Society FWCS

Dg\Vc^hVi^dch

SWHS Serbian Wound Healing Society www.lecenjerana.com

The HZgW^Vc LdjcY =ZVa^c\ HdX^Zin was established in December 2006 in Belgrade as an effort for the organized and coordinated approach to the area of wound management.

The Society promotes multidisciplinary involvement and cooperation among medical care providers dedicated to wound management.

We are proud to be a EWMA cooperating organization since 2007.

SWHS is the first institution in Serbia that spreads modern attitudes in the area of wound healing. Through the activities of the chronic wound treatment school and workshops we educate doctors and nurse how to treat patients with wounds.

intention is to create a place for experience and knowledge exchange. Authors from neighboring countries are welcomed to submit papers.

We started with a new activity in 2008 – TELEULCER. Teleulcer offers doctors and nurses a possibility to present selected cases of wounds and to get advices about the initial treatment and treatment plan from experts. Teleulcers is available on the Society web site – www.lecenjerana.com.

Our enthusiasm and high level of professionalism, initiated intensive presence of wound care companies in Serbia. Some new appeared and those already present increased there activities.

250 doctors and nurses attended our education modules so far. But, our credo is quality in front of quantity. We limit groups to 30 to 40 participants, so lectures are interactive and workshops are real hands on.

In the future we plan to continue with the intensive activities. We are looking forward to establish cooperation with the regional wound healing associations. Naturally, reaching high EWMA standards of organized In 2007, Society published first issue, volume 1 and coordinated approach to the area of and 2 of the journal “Rane” (Wounds). The Wound Management is our priority.

7th Scientific Meeting of the

Conference theme

Diabetic Foot Study Group

Advancement of knowledge on all aspects of diabetic foot care

of the EASD

Main subjects during conference: . Epidemiology . Basic and clinical science . Diagnostics . Classification . Foot clinics . Biomechanics, Osteoarthropathy . Orthopaedic surgery . Infection . Revascularisation . Uraemia . Wound healing/outcome

11-13 September 2008

Lucca, Italy

www.dfsg.org )-

:LB6

Journal 2008 vol 8 no 2

COPA FOAM DRESSINGS OUTPERFORM THE LEADING COMPETITION IN FLUID CAPACITY

0 15

9 8 7

COPA FOAM DRESSINGS PROVIDE MAXIMUM PATIENT COMFORT

8

Absorptive capacity (cc/in2) higher figure is more absorbent

7.8

30

Softness (N/cm) lower figure is softer

20.7

45 60

6

75

5

4.8

4

90 105

3

2.7

2

120

1

135

0

150 COPA

Alleryn

Polymem

120.5 COPA

Alleryn

Polymem

Cooperating Organisations AFIScep.be

GNEAUPP

Wound Management Association in Belgium

Grupo Nacional para el Estudio y Asesoramiente en Ulceras por Presión y Heridas Crónicas www.gneaupp.org

AISLeC Italian Nurse Association for the Study of Cutaneous Wounds www.aislec.it

AIUC Italian Association for Cutaneous Ulcers www.aiuc.it

APTFeridas

GWMA Greek Wound Management Association

ICW Initiative Chronische Wunden www.ic-wunden.de

LBAA

Portuguese Wound Management Association www.aptferidas.com

Latvian Wound Treating Organisation

AWA

LUF

Austrian Wound Association www.a-w-a.at

The Leg Ulcer Forum www.legulcerforum.org

BFW

LWMA

Belgian Federation of Woundcare www.befewo.org

Lithuanian Wound Management Association

CNC Clinical Nursing Consulting – Wondzorg www.wondzorg.be

CSLR Czech Wound Management Society www.cslr.cz

CWA Croatian Wound Management Association www.kbd.hr/index.php?id=799

MSKT Hungarian Lymphoedema and Wound Managing Society www.euuzlet.hu/mskt/

NATVNS National Association of Viability Nurse Specialists (Scotland) www.natvns.com

NIFS DGfW Deutsche Gesellschaft für Wundheilung www.dgfw.de

DWHS

Danish Wound Danish Wound Healing Society Healing Society www.dsfs.org

FWCS Finnish Wound Care Society www.suomenhaavanhoitoyhdistys.fi

Norwegian Wound Healing Association www.nifs-saar.no NOVW Dutch Organisation of Wound Care Nurses www.novw.org

PWMA Polish Wound Management Association www.ptlr.pl

ROWMA GAIF Grupo Associativo de Investigacão em Feridas www.gaif.net

Romanian Wound Management Association www.artmp.ro

SAfW Swiss Association for Wound Care www.safw.ch www.safw-romande.ch

*%

:LB6

Journal 2008 vol 8 no 2

Dg\Vc^hVi^dch

SEBINKO

SAWMA

Hungarian Association for the Improvement of Care of Chronic Wounds and Incontinentia www.sebinko.hu

Serbian Advanced Wound Management Association

SFFPC

Tissue Viability Nurses Association www.tvna.org

TVNA

La Société Française et Francophone de Plaies et Cicatrisations www.sffpc.org

TVS Tissue Viability Society www.tvs.org.uk

SSiS

WMAI

Swedish Wound Care Nurses Association www.sarsjukskoterskor.se

Wound Management Association of Ireland www.wmaoi.org

SSOOR Slovak Wound Management Association

WMAK

SUMS

Wound Management Association of Kosova

Iceland Wound Healing Society www.sums-is.org

WMAS Slovenian Wound Management Association

SWHS Serbian Wound Healing Society www.lecenjerana.com

WMAT

SWHS

Wound Management Association Turkey www.yaradernegi.org

Swedish Wound Healing Society www.sarlakning.se

;dg bdgZ ^c[dgbVi^dc VWdji :LB6¼h 8ddeZgVi^c\ Dg\Vc^hVi^dch eaZVhZ k^h^i lll#ZlbV#dg\

Associated Organisations Leg Club

LF

LSN

Lindsay Leg Club Foundation www.legclub.org

Lymphoedema Framework www.lymphoedemaframework.org

The Lymphoedema Support Network www.lymphoedema.org/lsn

EgZhZci ndjg cVi^dcVa ldjcY bVcV\ZbZci dg\Vc^hVi^dc dg lg^iZ V gZedgi VWdji ndjg dg\Vc^hVi^dc¼h aViZhi bZZi^c\# ewma@ewma.org

9ZVYa^cZ [dg hjWb^ii^c\ eVeZgh [dg i]Z DXidWZg '%%- ^hhjZ ^h & 6j\jhi '%%-

:LB6

Journal 2008 vol 8 no 2

*&

( :Y^idg^Va 8Vgda 9ZVaZn

HX^ZcXZ! EgVXi^XZ VcY :YjXVi^dc * IgZVibZci d[ X]gdc^X ldjcYh l^i] Vjidad" \djh eaViZaZi"g^X] eaVhbV BVgXjh < g\Zc

&( Edan]ZmVc^YZ E=B7 VcY 7ZiV^cZ ^c ldjcY XVgZ bVcV\ZbZci @jgi @VZ]c! I]dbVh :WZgaZ^c

&. EVi^Zcih¼ ZmeZg^ZcXZ d[ ldjcY"gZaViZY eV^c/ 6c ^ciZgcVi^dcVa eZgheZXi^kZ :a^oVWZi] ? BjY\Z

(& :[ÄXVXn d[ ]dcZn Vh V YZhadj\]^c\ V\Zci/ dkZgk^Zl d[ XjggZci Zk^YZcXZ <Zdg\^cV <Zi]^c

:7LB (+ 6WhigVXih d[ gZXZci 8dX]gVcZ GZk^Zlh HVaan 7Zaa"HnZg

:LB6 )% LdgaY Jc^dc d[ LdjcY =ZVa^c\ HdX^Zi^Zh 8dc\gZhh '%%9dj\aVh BXFjZZc

)' :LB6 ?djgcVa EgZk^djh >hhjZh )' >ciZgcVi^dcVa ?djgcVah )) :LB6 8dgedgViZ Hedchdgh 8dciVXi 9ViV )* =VgY"id"]ZVa LdjcYh · V ]da^hi^X VeegdVX]! i]Z :LB6 Edh^i^dc 9dXjbZci '%%8]g^hi^cZ Bd[[Vii

8dc[ZgZcXZh )+ 8dc[ZgZcXZ 8VaZcYVg

Dg\Vc^hVi^dch ), H:7>C@D! =jc\Vg^Vc 6hhdX^Vi^dc [dg i]Z >begdkZbZci d[ 8VgZ d[ 8]gdc^X LdjcYh VcY >cXdci^cZci^V )- HL=H! HZgW^Vc LdjcY =ZVa^c\ HdX^Zin *% 8ddeZgVi^c\ Dg\Vc^hVi^dch *& 6hhdX^ViZY Dg\Vc^hVi^dch